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1. INTRODUCTION 
 
An ideal drug therapy was based on relating pharmacological response to the 
dose administered. Poor correlation between the dose administered and 
pharmacological responses will be resulted because of the decreased absorption rate 
or poor dose rate. Deviation in the plasma drug concentration also will result due to 
the formulation factors and elimination characteristics resulting in toxicity. To reduce 
these problems an appropriate dosage regimen should be selected, which would attain 
the plasma concentration immediately after the administration and it should also kept 
the drug concentration below the maximum safe concentration. This possible by the 
administration of conventional dosage form in a particular dose at a particular 
frequency and should be convenient to patient for the administration.1 
 
  Drugs may be administered in various routes in a variety of dosage forms. The 
most important and popular route of administration is oral route. Because of its 
popularity and convenience almost every new drug that is newly developed will be 
tested for its effectiveness as an oral dosage form   during its initial stages of 
formulations.  
 
  Dosage forms that are administered through the oral routes are syrups, 
suspension, elixirs, capsules and tablets. Among these tablets and capsules are the 
most popular and convenient oral dosage formulations. Tablets offer best protection 
of the drugs against light, temperature, humidity, oxygen and moisture. Thus it will 
provide increase stability to the drug and the tablets are tampering proof dosage form. 
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1.1. Oral Drug Delivery System 
 
Oral drug delivery has been known for decades as the most widely utilized 
route of administration among all the routes that have been explored for the systemic 
delivery of drugs via various pharmaceutical products of different dosage forms. 
 
  All the pharmaceutical products formulated for systemic delivery via the oral 
route of administration, irrespective of the mode of delivery (Immediate, Sustained 
or Controlled release) and the design of dosage forms (either solid, dispersion, or 
liquid), must be developed within the intrinsic characteristics of GI physiology.2 As 
shown in the table no.1 
 
The most sophisticated delivery system, the greater is the complexity of these 
various disciplines involved in the design and optimization of the system. In any 
case, the scientific framework required for the successful development of an oral 
drug delivery system consists of a basic understanding of the following three aspects: 
 
1) The anatomic and physiologic characteristics of the gastrointestinal tract. As 
shown in below     table. 
2) Physicochemical, pharmacokinetic and pharmacodynamic characteristics of the 
drug. 
3) Physicomechanical characteristics and the drug delivery mode of the dosage form 
to be designed. 
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Anatomic and physiologic characteristics of the gastrointestinal tract 
Table No.1 
Region 
Surface Area 
(m2) 
pH of The 
Region 
Transit Time 
Fluid Solid 
GIT 200 1-8 - - 
Stomach 0.1-0.2 1-3.5 50 min. 8 hrs. 
Small intestine 4500 5-7.5 2-6 hrs. 4-9 hrs. 
Large intestine 0.5-0.1 6.8 2-6 hrs. 1hrs to3days 
 
 
1.2. TABLETS3 
Tablets are defined as solid pharmaceutical dosage forms containing 
medicament with or without suitable excipients and prepared either by compressing or 
moulding. 
 
Advantages of tablet 
• Unit dosage form and dose precision 
• Low cost 
• Special release profile  
• Better stability 
• Better patient compliance  
 
Disadvantages of tablets 
• Some drugs resist compression in to dense compacts. 
• Drug with low dissolution, poor wetting, optimum absorption of drug from 
gastro intestinal tract  will cause difficulty in formulating tablets 
• Bitter tasting drug, drugs with objectionable odour or drug sensitive to 
moisture are difficult to formulate as tablets 
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1.3. Manufacturing of tablets 
 
Granulation3,51 
Granulation is the process of collecting particles together by creating bonds 
between them. Bonds are formed by compression or by using binding agent. 
Granulation process is the most important process in the tablet making steps; a tablet 
with good characteristic is not made in the tablet press but in granulation process. 
Joining the particle with in a granulation process will improve flow and compression 
characteristic, reduce segregation, improve uniformity and eliminate excessive 
amount of fine powders. A fine granulation process will yield a reduced defect, 
increased yield and reduced time in tablet production. The best course of action is to 
ensure each tablet containing same amount of the active drug is by mixing the active 
thoroughly with some or most of the active ingredients and then granulate the blend. 
Each granule should contain small amount of active ingredient and other ingredients 
in evenly amount. If the active ingredient is high in quantity it should be granulated 
with itself if they have appropriate compressibility properties. The granulation process 
is the most important process in the tablet manufacturing process, three basic 
techniques are used to prepare granules for the compression of the tablets they are 
• Direct compression 
• Wet granulation 
• Dry granulation  
 
Direct compression 
In this process the drug materials are compressed directly, the compression of 
a single substance does not produce an acceptable disintegration. For disintegration 
problem other substance are added to overcome. The flow property and the 
compressibility index of the excipients added along with the drug also will be an 
important factor in this type of compression method. Direct compression has some 
advantage of low labor input, a dry process fewest processing step and also have 
limitations like interaction of the diluent with drug substance. 
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Wet granulation51 
 When the drug substance and the diluent are fluffy, fine it will not stay in the 
blend causing problem in mixing and filling in the die cavity resulting in weight 
variation etc. the wet granulation is the process of addition of granulating agent 
usually liquid solution in to the powder which will help in the formation of bonds 
between the powder forming granules. The liquid solution can be an aqueous solution 
or non-aqueous solution depending up on the nature of the powder. The granules will 
be dried on a hot air oven to particular moisture content over dried granules will break 
up easily and producing small particles called fines. Fines do not flow well in to the 
die cavity and can result in tableting problems. 
 
Dry granulation51 
Dry granulation process is used to form granules without using a liquid 
solution because the product using will be sensitive to moisture an heat. Forming 
granules without liquid needs the powder to be compacting and densifying by the 
process called slugging. Slugging is done by the roller compactor to form a 
compacted powder and it is finally passed through the mill and blend before 
compression. 
 
Advantage of direct compression 
 Economical, fewer manufacturing steps, less processing time and low labor 
cost. 
 No moisture, heat and high compaction pressure. 
 Important effects on tablet disintegration. 
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1.4.   Classification of tablets3 
 
A. Oral tablets for ingestion 
• Compressed tablets  
• Multiple compressed tablets  
• Compression-coated tablets 
• Repeat-action tablets  
• Delayed-action and enteric-coated tablets  
• Sugar and chocolate –coated tablets  
• Film coated tablets  
• Chewable tablets 
• Layered tablets 
 
  B.  Tablets used in the oral cavity 
• Buccal tablets  
• Sublingual tablets  
• Troches and lozenges  
• Dental cones  
 
  C. Tablets administered by other routes  
• Implantation tablets  
• Vaginal tablets  
 
  D. Tablets used to prepare solutions  
• Effervescent tablets  
• Dispersible tablets  
• Hypodermic tablets 
• Tablet triturates  
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1.5. Dispersible tablets24 
Despite the increasing interest in controlled release drug delivery systems the 
most common tablets that are intended to be swallowed whole and to disintegrate and 
release their medicament rapidly in the gastro intestinal tract still remains the dosage 
form of choice. Dispersible tablets are uncoated or film-coated tablets intended to be 
dispersed in water before administration giving a homogeneous dispersion. Hence 
proper choice of disintegrants and its consistency of performance are of critical 
importance to the formulation development of such tablets. The administrations of the 
drugs to the elderly patients have become a major barrier in drug therapy, mainly due 
to the difficulty in swallowing disability. These tablets are dispersed in the water 
before administration. Dispersible tablets are well administered for the pediatric, 
dysphasic patients, mentally ill, unco-operative and nauseated patients, those with 
conditions of motion sickness, sudden episodes of allergic attack or coughing. The 
dispersible tablets are preferred dosage form of WHO for the pediatric and elderly 
patients. The WHO specify dispersible tablet particularly suitable for children from 5 
kg to 35 kg. The tablet disintegrates in to the water in to a pleasant tasting 
suspension.56 Dispersible tablets are manufactured mainly by direct compression, wet 
granulation and dry granulation. The dispersible tablet should disperse in the water 
with in 3 min to produce a uniform dispersion. Pharmacopoeia specify a dispersion 
test exclusively for dispersibility tablet, 2 tablets placed in 100 ml of water and stirred 
until completely dispersed. A smooth dispersion is produced, which passes through a 
sieve screen with a nominal mesh aperture of 710 µm. Due to the administration of 
the drug in the dispersed from the area of absorption of the drug will be high when 
considering the conventional tablets. Drug which shows instability in the water can be 
formulated. Drug which having unacceptable taste can be masked in dispersible 
tablet. Compression of the drug substance alone in to a tablet wouldn’t produce 
acceptable disintegration time. So to increase the disintegration time a disintegrating 
agent are added to promote the breakup of the tablet in to small fragments in the 
aqueous environment and their by increasing the available surface area and absorption 
of the drug. There are three method to in cooperate the disintegration agent to the 
tablet they are; a. Internal addition b. External addition c. Internal and External 
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addition.49 In a direct compression process, drug is blended with a variety of 
excipients, subsequently lubricated and directly compressed into a tablet. 
Disintegrants used in this type of formulation, simply has to break the tablet apart to 
expose the drug substance for dissolution. 
 
Advantages of dispersible tablet 
• They are easy to swallow, so easy administration for elderly and childrens. 
• Quicker onset of action. 
• The tablet can also be divided. 
• The bitter taste of the active substance can be masked in advance. 
• Improved tablet performance 
• Applicability across a wide range of drugs with different physicochemical 
properties. 
 
Disadvantages of dispersible tablet 
• These tablets contain high concentration of disintegrants that tend to weaken 
the tablet structure. 
• Hygroscopic properties of these tablets are high. 
• Stability will be altered with atmospheric condition. 
• Inaccurate dosing. 
• Dispersible tablets should need a proper packing for proper stabilization and 
safety of the products. 
 
1.6. Disintegrating agent25,50,37,38 
A drug given in an orally administered tablet must undergo dissolution before 
it can be absorb and transported in to the systemic circulation. For many drugs 
dissolution must be preceded by disintegration of tablet matrix. For tablet dissolution 
it is necessary to overcome cohesive strength introduced in to the mass by 
compression. Therefore usual practice of incorporating the disintegrating agent will 
overcome this. Disintegration is frequently considered a prerequisite for drug 
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dissolution, it is no matter assures that drug will dissolved and hence have the 
potential for satisfactory bioavailability.50  The development of fast dispersible tablet 
using super disintegrants has become popular for various reasons. For tablet 
containing sparingly water soluble drugs, the start of dissolution is often delayed by 
the poor wettability of tablet or slow liquid penetration into tablet matrix. This will 
result in increase in the disintegration time and retards the drug release. This can be 
overcome by the addition of super disintegrants. The superdisintegrants such as 
Croscarmellose sodium, sodium starch glycolate and Crospovidone are now 
frequently used in the formulation to improve the rate and extent of tablet 
disintegration thereby increasing the rate of drug dissolution.48 The total porosity and 
pore mean diameter decrease, when applied pressure increased and consequently the 
disintegration time increase. Under certain condition the superdisintegrants makes 
enough pressure pores of the tablets as to produce an efficient disintegration. 
Although the rate of capillary penetration in tablets of narrower pore size distribution, 
larger parts of pore structure participate in liquid uptake.    
                     
 There are three methods of incorporating disintegrating agents in to tablet: A. 
Internal addition (intragranular) B. External addition (Extragranular) C. Partly 
Internal and External49. In a direct compression process drug is blend with a variety of 
excipients, subsequently lubricated and directly compressed in to a tablet. 
 
There are mainly four main mechanism of action for the disintegrants they are,29,48,49 
1. Swelling 
2. Porosity and capillary action (wicking) 
3. Deformation 
4. Due to disintegrating particle/particle repulsive forces 
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1. Swelling 
General mechanism of action for tablet disintegration is swelling. Swelling is 
the mechanism in which the disintegrating effect is by swelling in contact with water 
the adhesiveness of other excipient in a tablet will be overcome causing the tablet to 
disintegrate. 
Example: Starch and Modified starch (Sodium starch glycolate). 
 
2. Porosity and Capillary Action (Wicking) 
Disintegration by capillary force is the main step in disintegration. When the 
tablet is put in a suitable medium, the medium will drawn up or “wicked” in to these 
pathways through the capillary action and causes the breakup of the interparticulate 
bond between the particle.The good disintegrating property of the tablet will be 
depend up on the wetting property of the ingredients. The major wetting property was 
brought to the excellent wicking property of the disintegrants.29 The water uptake of 
the tablet will be depends up on the drug and excipients and on tablet conditions. 
These type of disintegrants wil maintain a low interfacial tension and high porous 
structure. 
Example: Crospovidone. 
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3. Deformation 
During tablet compression, disintegrated particle get deformed and these 
deformed particles get in to normal form when they came in contact with aqueous 
medium.48 Swelling capacity of the starch was improved when the granules are 
extensively deformed during compression. Increased in the size of the starch granules 
will thus cause the breakup of the interparticulate bond in tablet. Starch is granules are 
widely studied for this property. 
Example: Starch Maize. 
 
 
 
4. Due to disintegrating particle/particle repulsive forces 
This explains the disintegration of tablet made with ‘nonswellable’ 
disintegrants. Guyot-Hermann has proposed a particle repulsion theory based on the 
observation that nonswelling particles also causes disintegration of the tablet. The 
repulsive force between the particles are the main mechanism of action of 
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disintegrants act by this mechanism, at lower concentration it will cause good 
disintegrating property and improved compressibility for the tablets. 
Example: Gellan gum 
 
 
 
Wicking and swelling were found to be the primary mechanism of action for 
tablet disintegration, while other mechanisms such as deformation and particle 
repulsion theory etc may play a role in particulate cases of tablet disintegration 
Advantage of Superdisintegrants49 
 
• Remarkable tendency on wetting causing rapid disintegration. 
• No lump formation on disintegration 
• Compatible with commonly used therapeutics agents and excipients. 
• Work equally effective in hydrophilic and hydrophobic formulations 
• Provides good mechanical strength to the tablet facilitating easy packing and 
transportation. 
• Does not stick to the punches and dyes. 
 
Disadvantages of use of disintegrants in direct compression formulation49 
• High concentration needed for optimum disintegration efficiency 
• Poor disintegration 
• Susceptibility to high compression forces which decrease the efficiency   
• Poor compression properties 
• Decreased disintegrating efficiency in hydrophobic formulations 
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1.7. Drug market value and resistance.  
 
Amoxicillin21,17,39,40,41 
  Amoxicillin is a semi synthetic antibiotic, an analogue of ampicillin, with a 
broad spectrum of bactericidal activity against many gram positive and gram negative 
organism. The main mechanism of action is amoxicillin binds to penicillin binding 
protein located inside the bacterial cell wall. Pencillins acrylates the pencillin 
sensitive transpeptidase C-terminal  domain by opening the lactum ring. This 
inactivation of the enzyme prevents the formation of a cross link of two linear 
peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall 
synthesis. The amoxicillin is used as amoxicillin trihydrate in oral preparation.17 
Amoxicillin trihydrate is likely white or almost white crystalline powder and it is well 
absorbed when given orally, with a bioavailability that appears to be much higher than 
excepted based on its physicochemical and biopharmaceutical properties and the pH 
partition theory. The trihydrate form is slightly soluble in water and its stability in the 
solid state is possibly related to the effect of the water content and hygroscopic 
behavior. Because of its poor solubility amoxicillin trihydrate can be considered as a 
drug candidate which may give rise to dissolution related bioavailability problem. 
 
Market value of the drug52,31 
  In spite of availability of many new generation antibiotics- Amoxicillin is still 
very popular. Its one of the most common antibiotics prescribed for children. 
Amoxicillin stands 5th in 2008 top generic drugs by total prescriptions. Export of 
amoxicillin has been growing for last 6 years at very healthy rate.  Market Size and 
Growth Overseas market of amoxicillin for 2008-09 is estimated to be Rs. 547 crores 
(USD 118 million). Total sale of all amoxicillin formulations at the end of March 
2004 was Rs. 150 crores (USD 33 million). Since then, the market has been growing 
at a very healthy rate of 24% CAGR (Compounded Annual Growth Rate) 10 countries 
account for 49% export of Amoxicillin. South Africa, Nigeria, Myanmar, Sri Lanka 
and Netherlands are top 5 export markets of Amoxicillin, as per analysis of shipment 
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records collected from 18 major seaports, airports and dryports. South Africa emerges 
as the largest market, accounting for 11.19% market share (2008-09) by value. 
Nigeria, Myanmar and Sri Lanka follows in quick succession. Africa and Middle east 
are the largest regional markets. 
 
Drug resistance53,54 
The amoxicillin have been widely used in the outpatient arena for the 
treatment of community acquired respiratory tract and mild to moderate infections, 
due to the continues use of this drugs results in the resistance of the many organism to 
the amoxicillin like antibiotics.36 In most Western countries, microbiological testing 
may be unnecessary in acute uncomplicated urinary tract infections, except for 
surveillance purposes  because in most cases urine culture and susceptibility testing 
cost more than the antibiotic treatment itself. The Infectious Diseases Society of 
America (IDSA) guidelines currently recommend empirically treating acute, 
uncomplicated bacterial cystitis in healthy adult, nonpregnant females with a 3-day 
course of double-strength trimethoprim-sulfamethoxazole in settings where the 
prevalence of sulfamethoxazole resistance is 10-20%.37 Alternative therapies for 
uncomplicated UTI include a fluoroquinolone, nitrofurantoin or fosfomycin, wherever 
sulfamethoxazole resistance is 10-20% .However, these guidelines may not be 
applicable in other countries such as India. The resistance pattern of community 
acquired uropathogens has not been extensively studied in the Indian subcontinent. 
This study was planned to identify the most common pathogens associated with 
community acquired urinary tract infections in India and to determine their antibiotic 
sensitivities. This epidemiological data is essential to help formulate guidelines on 
empirical antibiotic treatment of uncomplicated community acquired urinary tract 
infections in India. Most of the individual in India have acquired severe resistance to 
amoxicillin like antibiotics, this result in forcing the use of new or increased drug 
therapy.  
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LITERATURE REVIEW 
 
K.F.M.Pasqualoto26 et al., (2004), Amoxicillin tablets  were developed by direct 
compression using a factorial design. Eight different formulation were carried out and 
they were analyzed considering three levels:the type of microcrystalline cellulose, the 
presence or absence of spray-dried lactose, and the presence or absence of the super 
disintegrants agent, Croscarmellose sodium. Average weight, thickness and diameter, 
hardness,friability, amoxicillin concentration, disintegration time and dissolution 
profile were the parameters used for the tablets evaluation. 
 
Andries F.Marais27  et al., (2003) formulated directly compressed amoxicillin-
Avicel,Ac-Di-Sol. The fast disintegration of the tablet with in one to two minute is a 
prerequisite for improving the dissolution of furosemide. Ac-Di-Sol was and efficient 
disintegrant for furosemide tablet at low concentration. 
 
Sagar Bhise28  et al., (2009)  developed amoxicillin using solid dispersion (SD) with 
crospovidone, croscarmellose sodium and sodium starch glycolate  by using kneading 
technique. it was concluded that the solubility and dissolution of model drug 
furosemide was increased due to solid deposition of drug upon surface of hydrophilic 
and strongly swelling superdisintegrants which enhanced the wettability and 
dispersibility of poorly water soluble drug furosemide which is prerequisite step for 
poorly water soluble drug. 
 
Priyanka Nagar29  et al., (2011) developed orally disintegrating tablet (ODT) of 
amoxicillin trihydrate which rapidly disintegrate & dissolve in saliva and then easily 
swallowed without need of water which is a major benefit over conventional dosage 
form. In addition, patients suffering from dysphasia, motion sickness, repeated emesis 
and mental disorders prefer such preparation because they cannot swallow large 
quantity of water. Further, drugs exhibiting satisfactory absorption from the oral 
mucosa or intended for immediate pharmacological action can be advantageously 
formulated in such type of dosage form. 
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Admo Fini30  et al., (2008) selected tablet formulation, containing 26% amoxicillin 
and 5% crospovidone, disintegrates before the amoxycillin starts to swell. These 
tablets disperse in water within 40 s and show a crushing strength of 95 N. To develop 
an orodispersible tablet, a rotatable central composite design was applied to predict 
the effects of the quantitative factors mannitol and crospovidone as well as 
compression force on the characteristics of the tablet. Special emphasis was paid to 
the development of a wetting test, replacing the normal disintegration method. An 
optimum tablet formulation, containing 34% mannitol and 13% crospovidone, 
provides a short wetting time of 17 second and a sufficient crushing strength of 40 N. 
Fast dispersible tablets with acceptable hardness and desirable taste could be prepared 
within the optimum region. 
 
Mauro Cavinato31  et al., (2011) studied three common active pharmaceutical 
ingredients (amoxicillin, caffeine and acetylsalicylic acid) were used within the initial 
formulation. Drug load was 50% (on weight basis.Influences of drug particle 
properties (e.g. particle size and shape, hygroscopicity) on the granule growth 
behaviour were evaluated. Resistance of the wet mass to mixing was furthermore 
measured using the impeller torque monitoring technique. The observed differences in 
the granule growth behaviour as well as the discrepancies between the actual and the 
ideal drug content in the final granules have been interpreted in terms of related to 
torque measurements. On the other hand where penetration time was lower (e.g. 
acetylsalicylic acid-based formulations), the growth was much faster but uniformity 
content problem arose because of the onset of crushing and layering phenomena. 
 
Xiaorong He32  et al., (2008) investigated amoxicillin trihydrate and croscarmellose 
sodium (Ac-Di-Sol) in a direct compression formulation containing a poorly water 
soluble drug (albumin tanate) at high dosage investigated. An experimental design 
with two variables,applied pressure and concentration of Ac-Di-Sol, allowed the 
evaluation of microstructural, mechanical and disintegration properties of the tablets. 
Tablet properties evaluated were affected by both variables, while compression 
parameters were essentially dependent on applied pressure. The shortest disintegration 
time was found for mixtures more prone to plastic deformation and densification at 
same level of applied pressure. These mixtures also revealed a finer pore structure. 
The different rearrangement of disintegrant particles in powder mixture is suggested 
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to explain the dominant effect of the disintegrant bonding mechanism presented at a 
given mixture composition. 
 
Naz Haasan Huda33  et al., (2009) studied Amoxicillin Trihydrate capsules in water  
for 60 minutes using USP reference dissolution apparatus. All, except  two national 
brands ; complied with  the USP  in vitro dissolution specification  for drug release 
(not  less than 80% of the labelled amount of amoxicillin trihydrate should be 
dissolved in 60 minutes). Drug releases from those two brands were 75% and 67% 
respectively within the specified time period. 
 
A.N.Zaid34  et al., (2010)  evaluated two capsules Amoxicillin 500mg and one 
Amoxicillin 100mg tablet have similar bioequivalence parameter. For this purpose a 
randomized, two way, cross over, bioequivalence study, was performed in 24 healthy 
male, volunteers, divided in to two groups of 12 subjects each. One group was treated 
with standard and other with amoxicillin tablet. Blood samples were collected at fixed 
intervals and pharmacokinetic parameters were determined. 
 
Pirrre Leroy35  et al., (1992)  developed HPLC method and microbiological assay 
developed for measuring amoxicillin in calves plasma were used in pharmacokinetic 
studies of antibiotics following IM administration of the test compound. The samples 
were assayed by the two methods. The HPLC techniques included protein 
precipitation of plasma samples with trichloroacetic acids, isocratic elution on a 
reversed phase column. The microbiological method is by agar gel diffusion method. 
Both method show full selectivity with regard to endogenous compounds and a co-
administrated antibiotic. 
 
Theerasak Rojanarata36 et al., (2010) developed method for amoxicillin in 
pharmaceutical preparation was assayed by two enzymatic reaction. In this work the 
assay condition were studied and optimized and the method was validated. Good 
accuracy and precision were obtained when the method was tested with amoxicillin 
capsule and powder for oral suspension. No interference from common excipients in 
the formulations or degradation products was observed, this proposed assay was an 
ideal green analytical method suitable for the quality control of amoxicillin for the 
pharmaceuticals. 
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Pei-Yi Li37 et al., (2007) effect of amoxicillin on the cellular DNA integrity was 
studies, in which amoxicillin was added to the human or hamster cells in culture, and 
the DNA lesions induced by the drug were assessed by a comet assay with nuclear 
extract incubation. Amoxicillin rapidly induced DNA lesions in human cells. The 
level of DNA lesions attained a maximum at about 1 h, and then declined steadily and 
reached almost the basal level at 6 h following the drug treatment. Similar induction 
pattern of DNA lesions was found with amoxicillin-related antibiotics such as 
ampicillin but not with the unrelated antibiotics such as kanamycin. Repair kinetics of 
the cells were treated with amoxicillin for only 1 h and continued culture in the 
absence of the drug for a certain period of time before subsequent analysis. Repair of 
the amoxicillin-induced DNA lesions was essentially completed within 4 
h.Amoxicillin induced intracellular reactive oxygen species (ROS) at the tempo 
similar to that of DNA lesions induction.  
 
Badraddin Mohammed Al-Hadiya38 et al., (2011) amoxicillin trihydrate suspension 
marketed as  Hymox  suspension as compared with the reference product, Amoxil 
suspension to healthy adult male subject under fasting conditions, for the purpose of 
registration, approval and marketing stage. The subjects received Hymox suspension, 
as a test product and Amoxil suspension as a reference in a single-dose, randomized, 
two way crossover design fashion on 2 treatment days, after an overnight fast of at 
least 10 hours, with a washout period of 7 days. Blood samples were collected at 
prespecified times over a period of 30 hours after administration. The bioanlaysis of 
clinical plasma samples was accomplished by an HPLC method, it found that the two 
formulations were considered to be bioequivalent. 
 
Giacomo Fontana39 et al., (2001) amoxicillin was loaded with Polyethyleneglycol 
(PEG)-coated polyethylcyanoacrylate (PECA) nanoparticles influence of the PEG 
coating on the particle size, zeta potential, drug release rate and phagocytic uptake by 
murine macrophages. Phagocytosis was evaluated by incubating amoxicillin loaded 
PECA nanoparticles with murine macrophages and determining the amount of 
phagocytized nanoparticles by dosing the amoxicillin present inside the macrophages 
of urease, the mucoadhesive properties of polyalkylcyanoacrylate nanoparticles and 
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the activity of the amoxicillin versus Helicobacter pylori, colloidal drug selivery 
system developed was suitable for the treatment against the Helicobacter pylori. 
 
K. Prakash40 et al., (2008) amoxicillin trihydrate in pharmaceutical bulk and tablet 
dosage was determined with spectroscopical method form using citro phosphate 
buffer pH 7.2. The system obeys Lambert-Beer’s law at 231 nm in the concentration 
range 2.5-50 µg/m. This methods have been successfully applied to the analysis of the 
bulk drug and its tablet dosage form. The methods have been statistically evaluated 
and were found to be precise and accurate. 
 
Zhepeng Liu41 et al., (2005) amoxicillin mucoadhesive microspheres were prepared 
using ethylcellulose as matrix and carbopol as mucoadhesive polymer for the 
potential use of treating gastric and duodenal ulcers. In vitro release test showed that 
amoxicillin released faster in pH 1.0 hydrochloric acid (HCl) than in pH 7.8 
phosphate buffer. Amoxicillin was not stable in an acidic surrounding. It was also 
found that amoxicillin entrapped within the microspheres could keep stable. In vitro 
and in vivo mucoadhesive tests showed that amoxicillin microsphere adhered more 
strongly to gastric mucous layer than non-adhesive amoxicillin microspheres could 
retain in gastrointestinal tract for an extended period of time. Studies showed that 
amoxicillin microsphere had a better clearance effect than amoxicillin powder did. 
The prolonged gastrointestinal residence time and enhanced amoxicillin stability 
resulting from the mucoadhesive microspheres of amoxicillin might make 
contribution to H. pylori clearance. 
 
Vinay Pandit42 et al., (2010) amoxycillin trihydrate was prepared as floating tablets. 
The formulations were prepared as matrix tablets in the form non effervescent tablets. 
Various grades of hydroxy propyl methyl cellulose were used to achieve controlled 
release of the drug. Granules were prepared by wet granulation technique and 
compressed into tablets. The prepared tablets were evaluated for weight variation, 
hardness, friability, drug content, buoyancy and in vitro dissolution studies. 
Optimized formulation of amoxicillin was found to have increased gastric residence 
prolonging the release of drug with 85% of drug release in 6 hours by diffusion. The 
mechanism of drug release was found to be diffusion and followed combination of 
zero order and first order kinetics.  
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N.Venkateswaramurthy43 et al., (2010) amoxicillin mucoadhesive microspheres, 
which have the ability to reside in the gastrointestinal tract for an extended period, 
were prepared. Amoxicillin microspheres were prepared by using Eudragit RL100 as 
matrix and carbopol 974P as mucoadhesive polymer. The microspheres were prepared 
by emulsion solvent evaporation technique. The prepared microspheres were 
evaluated with respect to the particle size, production yield, encapsulation efficiency, 
shape and surface properties, mucoadhesive property, invitro drug release and 
suitability for anti Helicobactor pylori effect. In conclusion, mucoadhesive 
microspheres of amoxicillin prepared in this study could stay in the gastrointestinal 
tract for a longer period of time. Which indicate a potential use of mucoadhesive 
microspheres of amoxicillin in treating H. pylori infection. 
 
Catherine Bisson-Boutelliez44 et al., (2010) amoxicillin and β cyclodextrin 
complexes were prpepared by two methods and then the interaction were determined. 
The extent of complexation in solution has been evaluated by high-performance liquid 
chromatography, nuclear magnetic resonance and 2D rotating-frame Overhauser 
enhancement spectroscopy. Mass changes calorimetric effects, and mass spectrometry 
were determined on the same sample under identical conditions using the Skimmer 
coupling system. Skimmer and infrared spectroscopy were used to characterize the 
solid state of the binary system. Complexation of AMOX with β-CD was proven by 
FT-IR, NMR, DSC, and HPLC. The 2D ROESY spectra did not show any dipolar 
proton interaction of the amoxicillin with cyclodextrin. The stability constant for 
amoxicillin with β-CD was determined. 
 
AidongWen45 et al., (2008) amoxicillin were determined simultaneously ambroxol in 
human plasma using clenbuterol as internal standard (IS). The plasma samples were 
subjected to a simple protein precipitation with methanol. Separation was achieved on 
a Lichrospher C18 column using methanol and water as a mobile phase by gradient 
elution at a flow rate of 1.0 mL/min. Detection was performed using electrospray 
ionization in positive ion multiple reaction monitoring (MRM) mode by monitoring 
the ion transitions. Calibration curves were linear in the concentration range of 5–
20,000 ng/mL for amoxicillin, and 1–200 ng/mL for ambroxol, with the intra- and 
inter-run. 
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Kiron S46 et al., (2011) amoxicillin tablets of different brands were selected for this 
study as amoxicillin molecule is highly sensitive to temperature and humidity. 
Adequate quantities of samples were procured from hospital and community 
pharmacies located in different regions of Kerala. Samples collected from different 
time intervals were suitably coded and analyzed for all the listed parameters. It was 
observed that, there were seasonal fluctuations in the Mean Kinetic Temperature and 
Mean Kinetic Humidity in the various regions of Kerala. The study data show that 
percentage strength of amoxicillin was least in samples collected from Cochin 
compared with those collected from other region of kerala.  Mean kinetic humidity 
was more in coastal area, which may have accelerated the degradation of amoxicillin 
in samples from Cochin. Microbiological data showed significant reduction in zone of 
inhibition for samples collected from Cochin in comparison with other regions.  
 
Sayaka Nakanishi47 et al., (2011) studied solid dispersion powder of indomethacin 
with Crospovidone shows useful characteristics for manufacturing dosage form. Four 
types commercial Crospovidone, polyplasdone XL used as the initial carrier. 
Polyplasdone Xl 10 and colidone were compared. The limit of the indomethacin-
crospovidone weight ratio with which a soild dispersion can prepared was calculated 
on the basis of heat of fusion of physical mixtures of indomethacin and Crospovidone 
with various weight ratios. 
 
Jinichi Fukami48 et al., (2006) prepared rapidly disintegration tablet in the oral cavity 
was prepared using glycine as a disintegrants. The effect of disintegrants and the 
disintegration behavior of the tablet in the oral cavity were evaluated. The wetting 
period from carboxymethylcellulose having the hardness  four kilo was three seconds 
.It does not affect the release of amoxicillin from the tablet. 
 
P.S Mohanachandran49 et al., (2011) used superdisintegrants to improve the 
efficacy of solid dosage forms. This is achieved by decreasing the disintegration time 
which in turn enhances drug dissolution rate. Disintegrants are substances or mixture 
of substances added the drug formulation that facilitates the breakup or disintegration 
of tablet or capsule content into smaller particles that dissolve more rapidly than in the 
absence of disintegrants. Superdisintegrants are generally used at a low level in the 
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solid dosage form, typically 1- 10 % by weight relative to the total weight of the 
dosage unit, various kinds of superdisintegrants which are being used in the 
formulation to provide the safer, effective drug delivery with patient's compliance. 
 
B.Preetha50 et al., (2004) studied croscarmellose sodium, sodium starch glycolate 
and crospovidone on dissolution of three model drugs with varying aqueous 
solubility, like carbamazepine , acetaminophen  and cetrizine HCl  from their 
respective tablet formulations prepared by wet granulation . Crospovidone in general 
was effective in improving the dissolution of the drugs used in the study and generally 
extragranular mode of addition seemed to be the best mode of incorporation, 
irrespective of the solubility of the main tablet component. 
 
T.Y.Puttewar56 et al., (2010) developed doxilamine orodispersible tablets were 
developed with considerable increase in drug release as compared to marketed 
formulations; seven formulations were developed and studied. To prevent bitter taste 
and unacceptable odor of the drug, the drug was taste masked with weak cation 
exchange resins like Indion 234, Indion 204 and Indion 414. The drug was 
characterized according to different compendia methods, on the basis of identification 
by UV spectroscopy,pH, organoleptic properties and other tests. Among the three 
resins, one was selected for further studies i.e., Indion 234, because of high drug 
loading capacity. Maximum loading was obtained at drug–resin ratio 1:2, pH 5, 
temperature 50°C and drug concentration 4 mg/ml. A successful taste masking of 
resinate was confirmed by time intensity method and also by taking drug release in 
0.01 N hydrochloric acid and in simulated salivary fluid. The optimized batch with 
disintegration time 25.24 ±0.75 and dissolution 100.46% ± 3.78.Compared with 
conventional marketed formulation and was found superior.  
 
Shaik Harun57 et al., (2011) prepared salbutamol sulfate using super disintegrating 
agents. Recently fast disintegrating drug delivery system have started gaining 
popularity and acceptance as new drug delivery system, because they are easy to 
administer and lead to better patient compliance. Direct compression technique was 
used as it requires conventional tablet machinery and thus economical process. 
Formulations containing Indion as super disintegrating agent show rapid in-vitro 
dispersion time as compared to other formulations.   
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A.Abdelbary62 et al., (2009) formulated famotidine ODT using the economic direct-
compression method. A 32 full factorial design was used to evaluate the influence of 
different excipients on the properties and in vitro dissolution of famotidine ODT. 
Disintegrants were studied in three levels viz. Ac-Di-Sol, sodium starch glycolate and 
low-substituted hydroxy propyl cellulose maximum dissolution and minimum oral 
disintegration time (11.4 s) were observed in optimized  prepared using L-HPC and 
mannitol. 
 
Simone Schiermeeier65 et al., (2009)  formulated ibuprofen to prevent bitter taste and 
side effects of the drug, the drug was associated with Phospholipon 80H, a saturated 
lecithin, by wet granulation. The granules were then coated using different film 
forming agents. Coated granules were then formulated with a sweetener  a mannitol-
based diluent  were added as superdisintegrants and compacted under low 
compression force. The eight lots of tablets were assessed if suitable as oral 
disintegrating tablets by determination of a range of technological parameters. 
Wetting and disintegration time matched with the requirements of for almost all these 
formulations. Dissolution profiles suggested that the combined action of the 
hydrophobic lecithin and the coating delay the release of the drug from tablets with 
respect to when it is free or in the form of simple granules. 
 
C.Ferrero66 et al., (1997)  developed croscarmellose sodium (Ac-Di-Sol) in a direct 
compression formulation containing a poorly water soluble drug (albumin tanate) at 
high dosage. An experimental design with two variables, applied pressure and 
concentration of Ac-Di-Sol allowed the evaluation of microstructural, mechanical and 
disintegration properties of the tablets. Tablet properties evaluated were affected by 
both variables, while compression parameters were essentially dependent on applied 
pressure. The shortest disintegration time was found for mixtures more prone to 
plastic deformation and densification at same level of applied pressure. These 
mixtures also revealed a finer pore structure. the results, consolidation mechanism and 
microstructure analysis should be performed while optimizing disintegration response 
in tablets formulated with a disintegrants mainly acting by swelling mechanism. 
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Kalpesh Gaur67 et al., (2011)  prepared aceclofenac by subliming method with two 
super-disintegrants, crospovidone and sodium starch glycolate were used in different 
ratio (2-8 % w/w) with camphor  as subliming agent. The prepared batches of tablets 
were evaluated for thickness, weigh variation, hardness, friability, drug content 
uniformity, wetting time, water absorption ratio, in-vitro disintegration time and in-
vitro drug release.  Among the three promising formulations, the formulation prepared 
by using 8% w/w of crospovidone and emerged as the overall best formulation based 
on the in-vitro drug release characteristics. 
 
Mohanchandran P.S68 et al., (2010)  formulated amlodipine besylate using different 
superdisintegrants were prepared by direct compression method. FDT’s were 
evaluated for its physicochemical properties and in vitro dissolution. Effect of 
different superdisintegrants on disintegration behavior of tablets was evaluated in 
phosphate buffer pH 7.2. All formulations were evaluated for precompression and 
post compression parameters. Wetting time of formulations containing 
croscarmellose sodium was least and tablets showed fastest disintegration. FTIR 
studies revealed that there was no physicochemical interaction between amlodipine 
besylate and other excipients. Optimized formulations showed short dispersion time 
with maximum drug release in 30 minutes. Combinations of super disintegrants were 
found to be better in the formulation of fast dissolving tablets of Amlodipine besylate 
rather than using alone. 
 
Sandeep B69 et al., (2009) formulated olanzapine, quick dispersing tablets by direct 
compression method. Effect of super disintegrant crospovidone on wetting time, 
disintegration time, drug content and in vitro release have been studied. A 32 factorial 
design was employed in formulating a quick dispersible tablet. The selected 
independent variables crospovidone and hydroxy propylcellulose showed significant 
effect on dependent variables i.e. disintegration time and percent drug dissolved. 
Disintegration time and percent drug dissolved decreased with increase in the level of 
crospovidone.  
 
Yoshio Kuno70 et al., (2008)  prepared OD tablets were produced by directly 
compressing a mixture containing lactose–xylitol granules, disintegrant, glidant and 
lubricant, and subsequent heating. The effect of the type of lubricant on the tablet 
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characteristics was evaluated using magnesium stearate (Mg-St), sodium stearyl 
fumarate (SSF), and talc as lubricants. The hardness of the tablets increased to as a 
result of heating, regardless of the kind of lubricant. The oral disintegration time of 
the tablets containing increased with an increase in the hardness. The oral 
disintegration time of the tablets containing talc was not changed despite of an 
increase in hardness.  
 
Grega Klancnik71 et al., (2010) comprised a group of techniques in which a physical 
property of a substance is measured to a controlled temperature program. The results 
given from the DTA or DSC curves depend on the preparation of the material, and on 
the instrument sensitivity. The sensitivity is in close relation to the apparatuses design. 
Several types of DTA and DSC apparatuses are described as well as the use. New 
types of DSC devices are being developed which will have the capability of high 
heating / cooling rates and with shorter response time. 
 
Rahul Chandrasekhar73 et al., (2009) studied series of hardness, fracturability and 
disintegration time tests were performed on the formulations at each stage. During 
Stage I, tablets were prepared in concentrations between 2% and 5% w/w, and were 
formulated at each concentration as single and combination bloom strength gelatin  
using 75 and 225 BSGs. Analysis revealed that both hardness and disintegration time 
increased with an increase in gelatin concentration. A combination FDT comprising a 
50:50 ratio of 75:225 BSGs (hardness: 13.7 ± 0.9 N and disintegration time: 24.1 ± 
0.6 s) was judged the most ideal, and was carried forward to Stage II: the addition of 
the saccharides sorbitol, mannitol and sucrose in concentrations between 10% and 
80% w/w.  
 
J.M Gines74 et al., (1995)  studied the analytical thermal techniques employed , 
differential scaning calometry(DSC) and hot stage microscopic, has demonstrated the 
ability of melted gelucire 53/10 to dissolve the crystals of cinnarazine. The high 
solubilizing effect of these vehicles, in comparison with other carriers, may be 
explained on the basis of its surfactants properties. Only at low drug percentages, can 
total dissolution of the cinnarazine present in the system be achieved. 
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Faizi Muzaffar75 et al., (2010) formulated amoxicillin microsphere were formulated 
by using solvent evaporation technique using Eudragit RS 100 matrix polymer. 
Evaluation of the prepared  microsphere were done for the percentage yield, particle 
size analysis, particle size distribution, angle of repose, and determination of the drug 
content, shape, surface characterization, drug entrapment. 
 
A.K.Hilton76 et al., (1992) investigated hydrophilic polymers were investigated for 
the preparation of amoxicillin trihydrate SR tablets. The most suitable system contain 
a 1:2 ratio of HPC to drug, which compressed easily and was not affected by 
alteration in normal compaction pressure. The dissolution showed that linear release 
of drug from matrix. Formulation of enhanced gastric retention time, by incorporation 
of gas-generating system, yielded either bilayer tablets which prematurely failed or 
large single layer tablet which remain buoyant for 6hours and showed satisfactory in 
vitro sustained release. 
 
N.Visavarungroj77 et al., (1990) studied cross-linked starches and pregelatinized-
crosslinked starches were evaluated as disintegrating agents in comparison to potato 
starch and a number of super-disintegrants such as Ac-Di-Soi, Explotab and 
Polyplasdone XL. The influence of disintegrants concentration, tablet hardness and 
tablet additives was evaluated by measuring the disintegration time of the tablets. 
Potato starch and the starches that were crosslinked only showed the lowest granule 
swelling power. The considerable swelling power achieved for the pregelatinized or 
pregelat starches, both the rate and amount of water uptake were observed to be low 
for these forms. 
 
Kimberley Jackson78 et al., (2000) studied physicochemical and physiological 
processes that can be altered by drug–excipient interactions and to explore 
mechanisms by which they might occur.  
 
Lucy S.C79 et al., (1989) observed glycolate to have a higher DT and lower water 
uptake at higher concentrations of the disintegrants. With, the DT increased with 
increasing viscosity of MC. This occurs despite an increase in water uptake by tablets 
containing higher viscosity MC. For tablets containing SiO, and MC, DT is extremely 
high. In the absence of MC, water uptake is slightly higher with the higher 
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concentration of SiO, but DT still remained high. Water uptake alone does not 
determine the disintegration process. The choice of excipients, especially binders such 
as methylcellulose, plays a crucial role in influencing disintegrants action. 
 
G.K.Bolhuis80 et al., (1997) studied as an effect of its lower swelling power, the 
super disintegrant crospovidone is far less effective than the other super disintegrants. 
Wet granulation of poorly soluble drugs with high concentrations of sodium starch 
glycolate resulted likewise in a strongly improved drug release and bioavailability 
from capsules and tablets. It was found, however, that granules containing a too high 
concentration of the super disintegrant slow down the drug release from tablets. This 
effect is caused by the formation of a viscous barrier of the super disintegrant in the 
granules during the dissolution process. 
 
Gopa Roy Biswas82 et al., (2011) prepared amoxicillin trihydrate by solid dispersion 
technique using modified gum karaya as a carrier. FTIR spectroscopy was performed 
to study drug polymer interactions. No drug polymer interaction was found. As 
confirmed by FTIR studies. The drug was dissolved in ethanol with continues stirring 
up to 30 min. Polymer was suspended in sufficient amount of water the drug solution 
was poured in to polymer suspension. The entire solvent was evaporated to 60°C-
70°C. Four formulation were prepared at adrug polymer ratio of 1:1,1:2,1:3,1:4. The 
result of solubility study showed with the increase in concentration of polymer. The 
modified gum karaya can be well utilized to increase to solubility of poorly water 
soluble drug amoxicillin trihydrate. 
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3.1. AIM AND OBJECTIVE 
The dispersible tablet is one of the most successful and famous dosage forms 
in the pharmaceutical market. Many of the dosage form that have been developed had 
not reached the market due to the high cost of manufacturing or due to the patient 
inconvenience but dispersible tablet have been dominating the market since the 
development of the dosage form. Dispersible tablet dosage form which is mostly 
prescribed in elderly, pediatric and aphagia patients. So the dispersible tablet is one of 
the most preferred dosage forms in the pharmaceutical market, WHO prefer 
dispersible tablet for elderly and paediatric patients. The market value of the 
dispersible tablet in developed countries is very high comparing to the developing 
countries. Most of the Indian pharmaceutical industries manufacture large value of 
dispersible tablet for the export. 
 
Amoxicillin is a semisynthetic aminopencillin with a broad-spectrum 
bactericidal activity used as trihydrate in oral preparation. Amoxicillin trihydrate have 
been widely used β lactum antibiotic in most of the African and European countries. 
Most of the antibiotic which are prescribed in the dispersible tablet dosage forms, due 
to the high manufacturing cost they are mostly manufactured developing countries 
like India, Brazil and china etc. it is one of the most profitable export business in the 
pharmaceutical industry and most of the industries in India have participated in this 
by making it a value of 547 crores at the year 2009-2010. By the proper management 
of the raw material and the method the export of the amoxicillin trihydrate can be 
more profitable and they can provide the patient in an affordable manner. 
 
In this work the challenge is to develop a formulation of amoxicillin trihydrate 
dispersible tablet of 320 mg in a low production value by using any method.  
Currently the industry is producing amoxicillin trihydrate dispersible tablet at much 
higher production rate, due to the high value of the raw material used in the industry.  
In this work tablets were developed using amoxicillin trihydrate which is purchased 
from a different supplier of lower price than the amoxicillin trihydrate currently using 
now, by the development of the tablet with this material, will results in tablets with 
low production rate. Earlier works done with the new material had resulted in the poor 
dissolution and disintegration of the tablet. So the entire preformulation and the 
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evaluation of the tablet have to be done to develop an economical amoxicillin 
trihydrate DT, which shows good dissolution properties and disintegration time. 
 
• Formulation and evaluation of dispersible tablets of β lactum antibiotic 
drug. 
• Improvement of the drug dissolution profile by disintegrants in the 
formulation. 
• To study the effect of disintegrants concentration on the dissolution 
profiles of drug containing formulations. 
• To determine the chemical compatibility of formulation containing various 
ratio of polymer and drug. 
• To study the stability of the drug in different environmental condition. 
• To determine the thermal stability of the drug and the tablet. 
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3.2.   PLAN OF WORK 
The study was planned to carry out as follows 
1. Procurement of drug, polymer and other excipients 
2. Preparation of mixed blend of drug and excipients by using super disintegrants 
3. Checking Drug and excipients compatibility by FTIR studies 
4. Evaluation of powder mixed blend of drug and excipients 
5. Compression of tablet by “Direct Compression method” 
6. Evaluation of compressed tablets 
7. In-vitro drug release 
8. DSC studies 
9. X-ray diffraction studies 
10. Stability testing of optimized batch 
11. Kinetics of drug release 
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5. Materials and Equipment used 
• List of Chemicals 
Table No.2 
Sl.No Materials Used Supplied by 
1 Amoxicillin trihydrate (Work) Zhuhai, China 
2 Dispersible cellulose Micro Labs, Banglore 
3 Starch Micro Labs, Banglore 
4 Maize starch Micro Labs, Banglore 
5 Crospovidone Micro Labs, Banglore 
6 Sodium starch glycolate Micro Labs, Banglore 
7 Croscarmellose Micro Labs, Banglore 
8 Magnesium Stearate Micro Labs, Banglore 
9 Colloidal Silicon Micro Labs, Banglore 
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• List of Equipments 
Tablet No.3 
Sl No Equipments Supplied by 
1 Single pan digital balance Mettler Toledo, Switzerland. 
2 Octagonal blender India octagonal blender, India. 
3 Tap Density Tester Electro Lab, India. 
4 Vernier Calipers Mitutoyo, USA. 
5 UV-Visible spectrophotometer UV 1700  shimadzu, Japan. 
6 Dissolution apparatus Lab India, India. 
7 Double rotary punching machine Cad Mach, India. 
8 Hardness tester Dr. Schleuniger, Switerland. 
9 Tablet Friabilator tester Electro Lab, India. 
10 Disintegration tester Electro Lab, India. 
11 Stability Chamber Newtronics, India. 
12 HPLC LC-2010 AHT, Japan. 
13 Moisture content analyser Medttler Toleo, Switerland. 
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5.1. DRUG PROFILE 
 
AMOXICILLIN TRIHYDRATE16,17,19,20,21,23,26 
Structure: 
 
 
Chemistry 
Molecular formula: C16H19N3O5S.3(H2O) 
IUPAC Name: (2S,5R,6R)-6-[[(2R)-2-Amino-2-(4-hydroxyphenyl)acetyl]amino]-
3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate. 
Molecular Weight: 419.45 
Melting Point:  194ºC 
PKa    : 9.48 
 
Solubility:  
Slightly soluble in water, very slightly soluble in ethanol (96 per cent), 
practically insoluble in fatty oils. It dissolves in dilute acids and dilute solutions of 
alkali hydroxides. 
 
Appearance: 
White or almost white, crystalline powder. 
 
Category: 
β lactum antibiotics 
 
Pharmacology: 
Used to treat bacterial infections caused by susceptible microorganisms 
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Mechanism of action17: 
Amoxicillin trihydrate interfere with the synthesis of bacterial cell wall. The 
bacteria synthesize UDP-N-acetylmuramic acid pentapeptide and UDP-N-acetyl 
glucosamine. The peptidoglycan residues are linked together forming a long strands 
and UDP spilt off. The final stage is cleavage of the terminal D-alanine of the peptide 
chains by transpeptidase; the energy so released is utilized for the establishment of 
cross linkages between peptide chains of the neighbouring strands. This cross linking 
provides stability and rigidity to the cell wall. The amoxicillin inhibit the 
transpeptidase so that the cross linking does not occur. 
 
Side effects26: 
Local irritancy and direct toxicity, hypersensitivity, candida stomatitis or 
vaginitis and rashes with intense itching, some cases of hepatic toxicity have been 
reported. 
 
Pharmacokinetics 
 
Absorption: 
Amoxicillin oral absorption is rapid and complete. Amoxicillin is rapidly 
absorbed by the gastrointestinal tract after oral administration and is stable in the 
presence of gastric acid. Food does not interfere with absorption. Peak serum 
concentrations are usually attained within 1 to 2 hours following oral administration. 
After the oral administration of 500mg amoxicillin trihydrate the Cmax is 6.0-15.3, 
tmax is 2 hour. The AUC( Area under the curve) ranged from 21.0 to 30.3 
mg/liter/hour with a mean of 27.4mg/liter per hour. 
 
Distribution: 
  Amoxicillin diffuses readily into most body tissue and fluids, with the 
exception of the cerebrospinal fluid; Pleural fluids, lungs, and peritoneal fluid; high 
urine concentrations are attained; also into synovial fluid, liver, prostate, muscle, and 
gallbladder; penetrates into middle ear effusions, maxillary sinus secretions, tonsils, 
sputum, and bronchial secretions, although higher concentrations of the drug may be 
attained in patients with inflamed meninges. Amoxicillin is not highly protein bound 
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about 17% - 20%. Its elimination half-life ranges from 0.7 to 1.4 hours in patients 
with normal renal function. Amoxicillin is partially metabolized to microbiologically 
inactive metabolites. 
 
Excretion: 
  Amoxicillin is excreted through urine (60% unchanged). Small amounts of the 
compounds are excreted in feces and bile.Half-life elimination of neonates is 3-7 
hours, infants and children 1-2 hours, adults with normal renal function 0.7-1.4 hours 
and renal impairment patient ( Clcr <10 mL/minute) is 7-21 hours. In healthy adult 
after the administration of 500mg amoxicillin by oral/ iv administration the mean 
amount of amoxicillin recovered unchanged in the urine over 24 h was 287.0 
mg(57.4%) after i.v. dosage and 217.1 mg (43.4%)after oral dosage. 
 
Drug  interactions: 
Regular use of probenecid or other renal acid secretory system inhibitors 
decrease renal secretion of amoxicillin and increase blood concentration of 
amoxicillin. Allopurinol administered with amoxicillin may increase the possibility of 
skin rash. Administration of amoxicillin with other bacteriostatic drugs may interfere 
with the bactericidal effect. Amoxicillin will decrease the effect of oral 
contraceptives. It is due to the inactivation of colonic flora which may interfere with 
deconjugation and enterohepatic cycling of oral contraceptives causes the failure of 
oral contraceptives some clinicians advise alternate dosage regimen for both drugs.  
 
It has contraindication in pregnancy state as it readily cross placenta. Its safety 
in treatment of infections during pregnancy has not yet established. Adverse effect has 
not yet been established. Amoxicillin appears in milk in low concentrations. The 
frequent administration of amoxicillin will result in diarrhea. It causes high incidence 
of rashes in patients with AIDS and lymphatic leukemia. Sometimes the rashes may 
be toxic in nature. It also produces local irritancy and direct toxicity, hypersensitivity 
like urticarial, angioedema, bronchospasm and jarisch –Herxheimer reaction. 
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Contraindication: 
Amoxicillin trihydrate is contra indicated in patients with: 
 Allergic to penicillin and other beta-lactam antibiotics 
 Allergic to any of the active ingredients in the medicine 
 Glandular fever 
 Asthma patient 
 Pregnant Patients 
 Breast feeding 
 Acute or chronic impairment 
 
Side effects: 
Patients administering amoxicillin trihydrate may suffer from mild side 
effects. These side effects may include: 
 Headaches 
 Gastrointestinal distress 
 Vomiting 
 Stomach aches 
 Swollen tongue 
 Development of white patches on the tongue and sides of the mouth. 
 Seizures 
 Nausea 
 Rashes with severe itching 
 Flu-like symptoms such as a fever and sore throat, along with changes to a 
 Mental or emotional disturbances 
 
Therapeutic use 
 Upper respiratory tract infection. 
 Genitourinary tract infection. 
 Skin and soft tissue infection.  
 Lower respiratory infection 
 Syphilis 
 Gonorrhoea 
 Diphtheria 
 Tetanus 
 Chronic urinary tract infections 
 H.pyloric infection 
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Dosage 
 
Adults: 
• Adult dose 250 mg every eight hours. 
• In Gonorrhoea 3 gm of amoxicillin with one gram of probenecid should be 
given as a single dose. 
• In severe infections or those caused by less susceptible organisms 500 mg 
every 8 hours for adults. 
 
Children: 
• 20 mg/kg/day in divided doses every 8 hours. 
• In gonorrhea, 50 mg/kg body weight and 25 mg of probenecid per kg of 
body weight should be given as a single dose. Probenecid is not 
recommended in children under 2 years of age. 
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5.2. POLYMER PROFILE4,18,25 
 
CROSSCARMELLOSE SODIUM 
 
Nonproprietary Names: 
 BP: Croscarmellose sodium 
 PhEur: Carmellosum natricum conexum 
 USPNF: Croscarmellose sodium        
                      
 Synonyms:  
 Ac-Di-Sol; cross linked carboxymethylcellulose sodium;  Explocel; modified 
cellulose gum; Nymcel ZSX; Pharmacel XL;  Primellose; Solutab; Vivasol. 
 
Functional Category: 
Tablet and capsule disintegrants. 
 
Chemical name:  
Cellulose carboxymethyl ether calcium salt. 
 
Empirical Formula and Molecular Weight:  
  The USPNF 23 describes carboxymethylcellulose calcium as the calcium salt 
of polycarboxymethyl ether of cellulose 
 
 
Structural Formula: 
 
 
                                                                                               Polymer Profile 
 
Dept. of Pharmaceutics, KMCP              Page 39 
 
Applications in Pharmaceutical Formulation or Technology: 
 Used as a disintegrant for capsules, tablets, and granules. 
 Croscarmellose sodium may be used in both direct-compression and wet-
granulation processes in tablet formulations.  
 Wicking and swelling ability of the disintegrant is best utilized when used in 
wet granulations. 
 Used both the wet and dry stages of the process (intra and extra granularly).  
 Croscarmellose sodium at concentrations up to 5% w/w may be used as a 
tablet disintegrant, 2% w/w is used in tablets prepared by direct compression 
and 3% w/w in tablets prepared by a wet-granulation process. 
 
 Uses of Croscarmellose Sodium: 
 
 
 
 
 
 
Description:  
Croscarmellose sodium occurs as an odorless, white or greyish-white powder. 
 
Incompatibilities: 
The efficacy of disintegrants, such as Croscarmellose sodium, may be slightly 
reduced in tablet formulations prepared by either the wet-granulation or direct-
compression process that contain hygroscopic excipients such as sorbitol. 
 
Croscarmellose sodium is not compatible with strong acids or with soluble 
salts of iron and some other metals such as aluminum, mercury and zinc. 
 
Stability and Storage Conditions: 
Croscarmellose sodium is a stable though hygroscopic material. 
Croscarmellose sodium should be stored in a well-closed container in a cool, dry 
place. 
Use Concentration (%) 
Disintegrant in capsule 10-25 
Disintegrant in tablets 0.5-5.0 
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SODIUM STARCH GLYCOLATE 
 
Nonproprietary Names: 
BP: Sodium starch glycolate 
PhEur: Carboxymethylamylum natricum 
USPNF: Sodium starch glycolate 
 
Synonyms: 
Carboxymethyl starch, sodium salt; Explosol; Explotab; Glycolys; Primojel; 
starch carboxymethyl ether, sodium salt; Tablo; Vivastar P. 
 
Chemical Name: 
  Sodium carboxymethyl starch. 
 
Empirical Formula and Molecular Weight: 
The USPNF 23 states that sodium starch glycolate is the sodium salt of a 
carboxymethyl ether of starch. 
 
The PhEur 2005 describes three types of material: Types A and B occurs as 
the sodium salt of a cross-linked partly O-carboxymethylated potato starch, 
containing 2.8–4.2% and 2.0–3.4% of sodium respectively. Type C is the sodium salt 
of a cross-linked by physical dehydration, partly O-carboxymethylated starch 
containing 2.8–5.0% sodium. 
 
Sodium starch glycolate may be characterized by the degree of substitution 
and crosslinking. The molecular weight is typically 5 × 105–1 × 106. 
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Structural Formula: 
 
                            
 
Functional Category: 
Tablet  and capsule disintegrant. 
 
 Applications in Pharmaceutical Formulation or Technology: 
 Sodium starch glycolate is widely used in oral pharmaceuticals as a 
disintegrant in       capsule and tablet formulations.  
 It is commonly used in tablets prepared by either direct-compression or 
wet-  granulation processes.  
 The concentration employed in a formulation is between 2% and 8%, 
with the optimum concentration about 4%. 
  Disintegration occurs by rapid uptake of water followed by rapid and 
enormous swelling.  
  By use of sodium starch glycolate, increasing the tablet compression 
pressure also appears to have no effect on disintegration time.  
 Sodium starch glycolate has also been investigated for use as a 
suspending vehicle.  
 
Description: 
Sodium starch glycolate is a white to off-white, odorless, tasteless, free-
flowing powder.  It consists of oval or spherical granules, 30–100 µm in diameter, 
with some less-spherical granules ranging from 10–35 µm in diameter. 
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Incompatibilities: 
Sodium starch glycolate is incompatible with ascorbic acid. 
 
Stability and Storage Conditions: 
Tablets prepared with sodium starch glycolate have good storage 
properties.Sodium starch glycolate is stable and should be stored in a well-closed 
container in order to protect it from wide variations of humidity and temperature, 
which may cause caking. 
 
 The physical properties of sodium starch glycolate remain unchanged for up to 
3–5 years if it is stored at moderate temperatures and humidity. 
 
CROSPOVIDONE 
Crospovidone is a cross-linked homopolymer of 1-ethenylpyrrolidin-2-one. It 
is available in different degrees of powder fineness (type A and type B). 
 
Molecular Formula: (C6H9NO)n-(C4H6O2)m 
 
Molecular Weight: 5000-70000 
 
Structural Formula: 
 
N
CH3
O
CH3
n
 
 
Description: White or yellowish-white powder or flakes, hygroscopic. 
 
Density, tapped: 0.35-0.45 gm/cm3 
 
Solubility: Practically insoluble in water, in alcohol and in methylene chloride. 
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Stability & storage conditions: Crospovidone is a stable and should be stored in a 
well-closed container in a cool and dry place. 
 
 
Incompatibilities: 
Crospovidone is incompatible with most inorganic and organic pharmaceutical 
ingredients. When exposed to high water levels, Crospovidone may form molecular 
adducts with some materials. 
 
Handling procedures:  
Eye protectors, gloves and dust mask are recommended. 
 
Uses:  
Crospovidone is used in oral pharmaceutical formulations and as a 
disintegrants for capsules, tablets and granules. 
 
DISPERSIBLE CELLULOSE 
Dispersible Cellulose is a colloid-forming, attrited mixture of Microcrystalline 
Cellulose and Carmellose Sodium. 
 
Synonym: Avicel RC 
 
Chemical Name:  
A cellulose having some of the hydroxyl groups in the form of the methyl 
ether 
 
Category:  
Pharmaceutical aid (lubrication, tablet and capsule adjuvants) 
 
Description:  
A white or off-white, coarse or fine powder. 
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Solubility:   
Soluble in water and when disperses in water producing a white, opaque 
dispersion or gel; practically insoluble in organic solvents and in dilute acids. 
 
Application and uses: 
Dispersible celluloses are used in pharmaceutical suspensions, emulsions, 
nasal sprays, and creams. The wide range of thixotropies, viscosities, gel strengths, 
and dispersion characteristics of this product line provide unparalleled suspension 
stability and functional versatility. 
 
Stability and Storage: 
Dispersible Cellulose should be stored at a temperature of 8°C to 15°C. 
 
MAIZE STARCH 
Maize starch is obtained from caryopsis of Zea mays L. 
 
Nonproprietary Name:  
B.P: Maize starch  
U S P: Starch  
Ph Eur: Corn starch  
 
Functional Category:  
Pharmaceutical Excipient 
 
Molecular Formula: 
 (C6H10O5)n 
 
Application in pharmaceutical Formulations: 
 Binding agent 
 Disintegrating agent  
 It is widely used as a filler or diluent in tabelts and in capsules. 
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Description:  
White to yellowish in colour, very fine powder with creaks when pressed 
between fingers. 
 
Solubility:  
Practically insoluble in cold water and ethanol (96%). 
 
Storage: Store in a cool dry place, avoid moisture. 
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5.3. EXCIPIENTS PROFILE4,18,15 
             
 MAGNESIUM STEARATE 
 
Nonproprietary Names 
BP: Magnesium stearate 
JP: Magnesium stearate 
PhEur: Magnesii stearas 
USPNF: Magnesium stearate 
 
Synonym  
 Magnesium octadeconate, Octadecanoic acid, Magnesium salt, Stearic acid, 
magnesium salt. 
 
Chemical name  
 Octadeconic acid magnesium salt. 
 
Empirical formula  
C36H70MgO4.  
 
Molecular weight 
591.34 
 
Composition  
The USPNF 23 describes magnesium stearate as a compound of magnesium 
with a mixture of solid organic acids that consists chiefly of variable proportions of 
magnesium stearate and magnesium palmitate (C36H70MgO4). The Ph. Eur 2005 
describes magnesium stearate as a mixture of magnesium salts of different fatty acids 
consisting mainly of stearic acid and in major proportions other fatty acids. 
 
Structural Formula  
 [CH3 (CH2)16COO]2Mg 
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Functional category  
Tablet and capsule lubricant 
 
 Pharmaceutical Applications 
 Magnesium stearate is widely used in cosmetics, foods and pharmaceutical 
formulations. 
 It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0%. 
 It is also used in barrier creams. 
 
Description  
 Magnesium stearate is a very fine, white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odor of stearic acid and a characteristic 
taste. The powder is greasy to touch and readily adheres to the skin. 
 
Incompatibilities  
 Incompatible with strong acids, alkalis and iron salts. Avoid mixing with 
strong oxidizing materials. Magnesium stearate cannot be used in products containing 
aspirin, some vitamins and most alkaloidal salts. 
 
Safety  
  Magnesium is generally regarded non-toxic following oral administration. 
However overconsumption of large quantities may cause laxative effect and mucosal 
irritation. No toxicity information is available relating to normal routes of 
occupational exposure. 
 
Stability/storage conditions 
Magnesium stearate is stable and should be stored in a well closed container in 
a cool dry place. 
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COLLOIDAL SILICON 
 
Nonproprietary Names 
BP: Colloidal anhydrous silica  
PhEur: Silica colloidalis anhydrica  
            USPNF: Colloidal silicon dioxide 
 
Synonym  
Aerosil ;Cab-O-Sil;Cab-O-Sil M -5P;colloidal silica;fumed silica;light 
anhydrous silicic acid;silicic anhydride; silicon dioxide fumed; 
 
Chemical name  
 Silica {7631-86-91} 
 
Empirical formula  
 SiO2 
 
Molecular weight 
 60.08 
 
Composition 
 Despite the fact that colloidal silica has the same chemical formula as quartz 
sand, SiO2, the two materials could hardly be more different in their effect on paper 
machine operations. The key difference is size. The subunits of colloidal silica 
particles are typically in the range of 1 to 5 nm. Whether or not these subunits are 
joined together depends on the conditions of polymerization. Initial acidification of a 
water-glass (sodium silicate) solution yields Si(OH)4. If the pH is reduced below 7 or 
if salt is added, then the units tend to fuse together in chains.  
 
Structural Formula  
 Sio2 
 
Functional category  
 Adsorbent, anticaking agent, tablet disintegrants, viscosity increasing agent. 
 
Pharmaceutical Applications  
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 Used in aerosols. 
 Emulsion stabilizer. 
 Glidants. 
 Suspending agent and thickening agent. 
 Tablet disintegrants. 
 
Description  
Colloidal silicon is a submicroscopic fumed silica with a particle size of about 
15 nm. It is a light, loose, bluish-white coloured, odourless, tasteless, gritty, fluffy 
powder.  
 
Incompatibilities  
Incompatible in diethyl stillbestrol preparations 
 
Safety  
 Intraperitoneal and subcutaneous injection may produce local tissue reactions 
and/or granulomas. 
 
Stability/storage conditions 
Colloidal silicon dioxide is hygroscopic but adsorbs large amount of water 
without liquefying. When used in aqueous systems at a pH 0±7.5, colloidal silicon 
dioxide is effective in increasing the viscosity of a system. 
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6. EXPERIMENTAL WORKS 
 
 Preformulation studies 
 Identification tests:13,44 
 
UV spectra:  
Amoxicillin trihydrate is dissolved in a suitable solvent and it was scanned 
at wavelength 200nm-400nm in which 0.1N HCL as a blank, using double beam 
UV/Visible spectrophotometer. The maximum wavelength was found to be 272nm.  
 
IR spectra:   
The IR spectra of drug in KBR pellets at moderate scanning between    
4000-400 cm-1 was carried out using FTIR (Perkin Elmer). The spectrum gives the 
peak value of the compound, when comparing with the standard value of the 
functional group. The sample was identified as pure amoxicillin trihydrate drug.  
  
Solubility:  
It is slightly soluble in water, ethanol (95%), and methanol. It is insoluble in 
chloroform, ether and in fixed oils. It is soluble in dilute solutions of acids and alkali 
hydroxides. 
 
Drug excipient compatibility studies:17 
Drug-Excipient compatibility studies form an important part of Preformulation 
studies. The interaction between the drug and excipients are determined after a 
specific time period by using suitable analytical technique like FTIR. 
 
Preparation of stock solution:33,34,40 
Amoxicillin trihydrate was accurately weighed and transferred in to the       
100 ml volumetric flask. It was dissolved in 0.1 N HCL and the volume were made up 
to the mark with 0.1 N HCL to get a 1000 µg/ml solution. 2 ml of the above solution 
was then further transferred in to another 100 ml standard flask and made up to 100 
ml with 0.1 N HCL to get stock solution of 20 µg/ml. 
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Preparation of Standard curve: 
From the stock solution 1 - 10 ml were pipetted out in to 10 ml volumetric 
flask and were made up to the mark with 0.1 N HCL to obtain amoxicillin  trihydrate 
concentration of  2 - 20 µg/ml respectively. Absorbance of each solution was 
measured at 272nm.  
 
Sl No. Concentration (mcg) Absorbance 
1 2 0.077 
2 4 0.144 
3 6 0.224 
4 8 0.291 
5 10 0.362 
6 12 0.440 
7 14 0.510 
8 16 0.581 
9 18 0.653 
10 20 0.725 
                                               
Calibration Curve 
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                                                                     Figure 1 
                                                                                                      Regression= 0.9999 
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Preformulation studies of pure drug and excipients:3,5,29,30,57,32 
It is the first step in the rational development of dosage forms of a drug 
substance, these studies focus on those physicochemical properties of the drug that 
could affect drug performance as an effective drug dosage form. Preformulation can 
also be defined as the investigation of physical and chemical properties of a drug 
substance alone or with excipients. It will provide the necessary information for the 
development of safe, stable and effective formulation. Following Preformulation 
studies are done with the sample drug.3 
 
Objective:  
The overall objective of preformulation testing is to generate information 
useful to the formulation in developing stable and bioavailable dosage forms. 
Scope: The use of preformulation parameters maximizes the chances in 
formulating an acceptable, safe, efficacious and stable product. 
 
Bulk Density (Db): 
Bulk density of a compound varies substantially with the method of 
crystallization, milling or formulation. It is of great importance when one considers 
the size of a high dose capsule product or the homogencity of a low dose formulation 
in which there are large differences in drug and excipient densities. In addition to bulk 
density, it is frequently desirable to know the true density of a powder for 
computation of void volume or porosity of packed powder beds. 
 
 Apparent bulk density is determined by taking weighed quantity of the powder 
(W)  in a graduated measuring cylinder and volume (V0) was measured, then bulk 
density was calculated by using the  formula, 
 
Bulk density = weight of powder/ volume of 
powder 
B.D. = W/V0 g/ml 
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Tapped Density (Di): 
Weighed amount of powder was taken in a graduated cylinder and the volume 
was measured (Vo). The graduated cylinder was fixed in the tapped densitometer and 
tapped on a hard surface from the height of 10 cm at 2 second interval until the 
difference in the volume after consecutive tapping was not changed. The final reading 
was denoted by (Vf) the volume of blend was used to calculate the tapped density, 
hausner’s ratio and Carr’s index. 
 
Tapped density =W/Vf g/ml 
 
 
Where W = Weight of the powder 
V0 = Initial volume 
                                                                     Vf = final volume 
 
Angle of repose (θ): 
The angle of repose is the measurement of the friction between the particles. 
Powder consists of individual particles of different size and shape. It is consider in the 
flow of the powder during the mixing of powders, flow of the powder in hopper, flow 
between die cavity and punches. It is the angle between free standing surface of 
powder and horizontal plane. Low value of angle of repose means flow of the 
particles or the friction between them is high. In these cases the friction between the 
particles can be increased by the use of friction reducing agent or “Glidants” eg: 
lactose. 
 
The Angle of Repose can be calculated using the formula : 
 Tan θ = h/r   
 h= height of the pile (cm) 
 r= radius of the pile (cm) 
 The powder was allowed to flow through a funnel fixed on a stand at a definite 
height (h) and powder will fall on the surface below the funnel forming a pile, radius 
of the pile is noted (r). Care was taken to see that the particle doesn’t fall or slip 
during the whole procedure.  
 
 Relationship between angle of repose and flow property is 
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Standard angle of repose as per flow properties 
Table No.4 
                  
                                    
                                         
  
 
 
 
 
 
 
 
Carr’s Compressibility Index:5,32 
An indirect method of measuring powder flow from bulk densities was 
developed by Carr. The percentage compressibility of a powder was a direct measure 
of the potential powder arch or bridge strength and stability. Carr’s index of each 
formulation was calculated according to equation given below:   
            
Carr’s Compressibility Index (%)   =      [(TD-BD) X 100] / TD 
            Where, TD = Tapped density and BD = bulk density 
                      
Relationships between % Compressibility and Flowability: 
Table No.5 
 
Sl. 
No. 
% Compressibility Flowability 
1 5 – 15 Excellent 
2 12 – 16 Good 
3 18 – 21 Fair  to Passable 
4 23 – 35 Poor 
5 33 – 38 Very Poor 
6 > 40 Extremely Poor 
Sl no Angle of repose Type of flow 
1 <20 Excellent 
2 20-30 Good 
3 30-40 Passable 
4 >40 Very Poor 
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Hausner’s Ratio:5 
 Hausner’s Ratio indicates the flow properties of the powder and is measured 
by the ratio of tapped density to bulk density
.
 It is the ratio of tapped density and bulk 
density. Hausner found that this ratio was related to inter particle friction and, as such, 
could be used to predict powder flow properties. Generally a value less than 1.25 
indicates good flow properties, which is equivalent to 20% of Carr’s index. 
 
 
 
 
Significance of Hausner’s ratio 
Table No.6 
Sl. No. 
Hausner’s 
Ratio 
Property 
1 0−1.2 Free flowing 
2 1.2−1.6 
Cohesive 
powder 
 
PREPARATION OF TABLETS:31-33,58-67 
 
Selection of tablet punching method 
While selecting the tablet punching method, compressibility character of the 
active substance and the excipients should be considered. For drugs, which are poorly 
compressible and have moderate to high dose, the wet granulation method would be 
followed. 
 
Drugs with low to moderate doses and good flow property direct compression 
method will be more advantages in term of economy, stability and performance. 
In this formulation amoxicillin trihydrate dispersible tablet are prepared mainly by 
wet granulation and direct compression.  
 
 
Hausner’s Ratio     =    Tapped density/Bulk Density 
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Selection of Excipients 
Excipients are as important as the active drug in a formulation. It will play an 
important role in the quality and action of the formulation. 
 
The following are used as excipients in the formulation of amoxicillin 
trihydrate dispersible tablet. 
 
Disintegrants77,78 
Less disintegration time and good dispersibility are the main characteristics of 
a good dispersible tablet. The necessity of the dispersible tablet is fast dispersion in a 
glass of water with less time. Some pharmaceutical ingredients require a binder for 
tableting. This provides the cohesiveness necessary for bonding together granules 
under compression. In such cases disintegrants are added to liberate the granules from 
this force and release the drug in to the solution. This demand results in the use of 
special disintegrants called “SUPER DISINTEGRANTS”. 
 
Disintegrants used in this formulation are maize starch, Sodium starch 
glycolate, Croscarmellose, Crospovidone and dispersible cellulose. 
 
 
Lubricants/Glidants 
Lubricant may be defined as a suitable material, a small amount of which 
interposed between two rubbing surface will reduce the friction arising at the 
interface. Mainly lubricants are intended to reduce the friction between the particles 
during the flow through the hopper and ejection of the tablet from the dies. In this 
formulation colloidal silicon and magnesium stearate are mainly used.  
 
Particle size 
The particle size range for direct compression tablets tends to be with in the 
100-200 µm range, mostly because of their required compaction behavior and powder 
flow properties. Smaller particles have higher absorption also the particle size have 
important effect in almost every step including mixing, granulation, compression etc.  
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The size of the particle is maintained by sieving process in which a particular 
size range of particle will be collected which will produce an appropriate 
characteristic of the tablet. 
 
Batch Calculation of Amoxicillin trihydrate dispersible tablet: 
Batch weight  =  Tablet weight×Batch size×Convertion factor 
                                                       1000×1000 
 
Convertion factor = Molecular weight of Amoxicillin trihydrate 
                                            Molecular weight of Amoxicillin  
                            
PREAPARATION OF AMOXICLLIN TRIHYDRATE DISPERSIBLE 
TABLETS 
 
Preparation of amoxicillin trihydrate dispersible tablets by Wet granulation 
method32,60-63,80 
           The amoxicillin trihydrate and other excipients were weighed as per the Table 
no. 7. Drug and the excipients were dry mixed for 15 mins using a planetary mixer. 
The mixture was transferred in to a RMG( Rapid mixing granulator), to the mixture in 
the RMG granulating medium (purified water) was added slowly for a period of 30-
180 sec at agitator on slow speed and chopper off till obtain an appropriate 
consistency,  add additional purified water if required to get the desired consistency. 
Each experiment was stopped immediately at the end of the liquid addition phase, 
hence wet massing was not performed, operate RMG for 30-180 sec at agitator and 
chopper fast speed for additional time to complete the granulation. During the process 
the mixer impeller and chopper were set at 300 rpm and 1300 rpm respectively. The 
total amount of the water added was adjusted according to the granule formation. 
 
Granules were dried by using a tray drier. Granules were spread uniformly on 
the tray and kept inside the tray drier, the temperature and time were set. The drying 
process is continued untill the moisture of the granules reaches a moisture content of 
12.4% to 13.4%. 
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 Dried granules were passed through the 22# (ASTM) sieve mesh. Finally 
magnesium stearate was added to the blend by passing through 22# (ASTM) sieve 
mesh. This blend is then mixed well and compressed in to tablet using rotary tablet 
machine. 
 
Preparation of amoxicillin trihydrate dispersible tablet by Direct 
compression33,62,63,81 
The amoxicillin trihydrate and other excipients were weighed accurately as per 
the Table no. 7, and then all the powders were passed through the 22# (ASTM) sieve 
mesh, except magnesium stearate which was passed through 22# (ASTM) sieve mesh. 
The whole blends were mixed in an octagonal blender for 5 min. Then the resulting 
blend was compressed in to tablets using a rotary tablet machine 
 
Tablet Size and Shape description. 
Shape and size description:  
Circular flat beveled edged tablet, with upper bisects and lower plain surface.  
B tooling tablets. 
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PREPARATION OF AMOXICILLIN TRIHYDRATE DISPERSIBLE TABLETS 
Table No.7 
287 mg of amoxicillin trihydrate = 250 mg amoxicillin 
 
Formulation Amoxicillin 
trihydrate 
(mg) 
Dispersible 
Cellulose 
(mg) 
Maize 
starch 
(mg) 
Crospovidone 
(mg) 
SSG  
(mg) 
Croscarmellose       
(mg) 
Mg 
Stearate 
(mg) 
Colloidal 
Silicon 
(mg) 
Total 
(mg) 
F1 287 - - 28 - - 4 1 320 
F2 287 - - - 28 - 4 1 320 
F3 287 - - - - 28 4 1 320 
F4 287 28 - - - - 4 1 320 
F5 287 - 12.95 15.05 - - 4 1 320 
F6 287 - 12.95 - 15.05 - 4 1 320 
F7 287 - 12.95 - - 15.05 4 1 320 
F8 287 - 9.33 9.33 9.33 - 4 1 320 
F9 287 - - - 14 14 4 1 320 
F10 287 - - 14 - 14 4 1 320 
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EVALUATION OF TABLETS42,64-70 
Hardness test: 
Tablet requires a certain amount of strength or hardness and resistance to 
withstand mechanical shock of handling in manufacture, packing and shipping.  
Hardness tester measured the hardness of tablet. Five tablets from each batch were 
used for hardness studies and results were expressed in Newton. 
 
Thickness and diameter: 
The thickness and diameter of tablets was carried out using Vernier caliper. 
Five tablets were used for this test from each batch, results were expressed in 
millimeter. 
 
Weight variation test: 
Twenty tablets were selected at random, individually weighed in a single pan 
electronic balance and the average weight was calculated. The uniformity of weight 
was calculated. The uniformity of weight was determined according to I.P. 
specification. As per U.S.P not more than two of individual weight should deviate 
from average weight by more than 7.5% and none deviate more than twice that 
percentage.  
 
Friability test: 
It was done in Roche Friabilator apparatus where the tablets were subjected to 
the combined effect of abrasion and shock by utilizing a plastic chamber that revolve 
at 25 rpm dropping the tablets at a distance of six inches with each revolution. 
Preweighed samples of 20 tablets were placed in the Friabilator, which is then 
operated for 100 revolutions. The tablets were then dusted and reweighed. 
Conventional compressed tablets that lose less than 0.5 to 1.0% of their weight are 
generally considered acceptable.                             
                            % F = {1-(Wt/W)} ×100 
                          where % F = Friability in percentage 
                                       W = Initial weight of tablets 
                                      Wt = Weight of tablets after revolution 
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   Dispersibility test64 
 2 tablets were placed in 100 ml of distilled water and stirred until completely 
dispersed. A smooth dispersion is produced, which passes through a sieve screen with 
a nominal mesh aperture of ASTM # 22. 
 
Disintegration test65 
One tablet was kept in each tube of the disintegration apparatus, suspended the 
assembly in the beaker containing water and operated with the discs for 4 minutes, 
unless otherwise stated in the individual monograph. Remove the assembly from the 
liquid.   
 
Dispersible tablet should complete the disintegration within 3 minutes in water  
(temperature 15°C to 25ºC). 
 
Dissolution studies 
 
In vitro dissolution test 
 
  Dissolution studies of all tablets were performed using dissolution tester 
(Paddle type, TDL‐08L, Electrolab, India). Tablets were added to the 900 ml of 0.1 N 
HCl at 37°C ± 0.5°C, which was stirred with a rotating paddle at 75 rpm. At time 
intervals of 15 minutes, 1ml samples were withdrawn and equal volume of fresh 
medium prewarmed at the same temperature was replaced in to the dissolution 
medium after each sampling to maintain its constant volume throughout the test. 
Assay carried out using U.V. spectrophotometer (UV 1700 shimadzu /Visible double 
beam spectrophotometer, Japan) at 272nm. 
 
Details of dissolution test:  
• Dissolution test apparatus  :  USP II (Paddle) 
• Speed     :  75 rpm                                                                              
• Volume of medium   :  900 ml                                                           
• Time interval                                     :  5,10,15,20,25,30,35,40 
• Medium used    :  0.1 N HCl 
• Temperature    :  37 ± 0.5 0C 
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Assay of tablets (HPLC Method)35,36,13,45 
Diluent solution 
13.6gm of monobasic potassium phosphate was dissolved in 2000ml of water 
and adjust to pH 5.0 ± 0.1 with 45% (w/w) solution of KOH. 
 
Preparation of standard solution 
115mg of amoxicillin trihydrate WS (working standard) was weighed 
accurately and transfer to 100 ml volumetric flask, 80ml diluent was added and 
sonicated at room temperature to dissolve the sample and was diluted to the volume 
with the diluent. The diluent was filtered through 0.45µ nylon membrane filter, 
discarding first few ml of filtrate. 
 
Sample preparation 
5 tablets were weighed and noted, then transferred in to 500ml volumetric 
flask and 350ml of diluent were sonicated for 5 min and diluent was made up to the 
mark and a magnetic stirring bar was placed and stirred for 30 min. The content was 
filtered and made up to 25ml.  
 
Procedure 
                    Inject the above solutions as per the following sequence 
                                                     Table No.8 
Injection solution No of injection Interpretation/calculate 
Standard 5 To calculate the % RSD 
Test solution a1 1 To calculate % of assay 
Test solution a2 1 To calculate % of assay 
 
Calculation  
 
Percentage amount of amoxicillin trihydrate  
 
             sample area × standard weight×500 × 25 × (purity of std) × (100-w) × avg. wt 
=        
                      standard area × 100 × sample weight × 10 × 100 × 100 
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STANDARD CURVE OF HPLC METHOD 
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DIFFERENTIAL THERMAL ANALYSIS (DTA)71-76,80 
Thermal analysis comprises a group of technique where the properties of the 
material are studied as they change with the temperature. To determine the thermo-
physical properties several methods are commonly used differential thermal analysis 
(DTA), differential scanning analysis (DSC), dilatometry (DIL), evolved gas analysis 
(EGA) etc. in pharmacy the main application of the DTA is used for the studying the 
phase transition under different atmospheric influence, temperature and heating1. 
DTA is a method for determining the temperature of the phase transition like melting 
point, solidification onset, re-crystallization onset etc. Analytical work in the area of 
TGA included compositional analysis of drugs, the volatile components of substance, 
effects of water vapor on the stability of crystalline drugs and excipients. The purpose 
of this study was to examine the thermal stability of the optimized formulation by the 
combined use of DTA and TGA. 
 
The DTA analysis was carried out to identify the compatibility between the 
drug and the excipients. The DSC analysis of the optimized formulation and Pure 
drug were carried out using ASTM E-537-98, TA instruments Inc. Samples were 
weighed and heated in a platinum cups with the reference material calcined alumina at 
rate of 10°C between 30°C to 600°C under the nitrogen atmosphere. 
 
X-RAY DIFFRACTION STUDIES83-85,87,88 
The interaction of the drug and excipients were determined by the X-ray 
diffractometer under the following condition: target/filter (monochromator) Cu, 
voltage 40 Kv, current 30mA, receiving slit 0.2 inches. The data were collected in the 
continue scan mode. The scanned range was 0 to 80°. 
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STABILITY STUDIES46,79,82,90-92 
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity, and light, and to establish a re-
test period for the drug substance or a shelf life for the drug product and 
recommended storage conditions. 
 
The choice of test conditions defined in ICH guideline is based on an analysis 
of the effects of climatic conditions in the three regions of the European countries, 
Asian and the United States. The mean kinetic temperature in any part of the world 
can be derived from climatic data, and the world can be divided into four climatic 
zones, I-IV. This guideline addresses climatic zones I and II. The principle has been 
established that stability information generated in any one of the three regions of the 
European countries, Japan and the United States would be mutually acceptable to the 
other two regions, provided the information is consistent with this guideline and the 
labeling is in accord with national/regional requirements. The stability studies 
conducted in this work are mainly based on the ICH guide lines. 
 
The stability studies were conducted by storing the tablet in a stability 
chamber at 30ºC / 65% RH and 40ºC / 75% RH for three months, the tablet physical 
properties and dissolution were examined once in a month. Each tablet were wrapped 
in an aluminum foil and packed in black PVC bottle and stored for three month. After 
one month tablets, were analyzed for its physical properties and dissolution 
properties. 
 
ANALYSIS OF RELEASE DATA93,6 
To analyze the mechanism of release, the best formulation was subjected to 
some statistical tests. The release data obtained were treated according to zero-order 
(cumulative amount of drug release versus time), first-order (log cumulative 
percentage of drug remaining versus time), Higuchi (cumulative percentage of release 
versus square root of time) and Korsmeyer-Peppas (log cumulative percentage of drug 
released versus time) equation models. 
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7. PRODUCTION COST COMPARISON 
 
Comparison of production cost of Marketed formulation Vs optimized 
formulation 
 
The optimized formulation price has been compared with the innovator 
formulation in the production cost, which has been found out that the optimized 
formulation has less production cost, the economical value of the dosage form has 
decreased and found to be a successful formulation. The below table shows the 
results.  
                                                    Table No.9 
 
 
  
Ingredients Price/kg 
Dosage 
form 
price/10 
tablet 
Ingredients Price/kg 
Dosage 
form 
price/10 
tablet 
Amoxicillin 
trihydrate(Work) 
1500 
 
4.37 
Amoxicillin 
trihydrate(Marketed 
formulation) 
2000 
 
 
5.84 
Crospovidone 350 
 
 
Crospovidone 
 
 
 
 
350 Croscarmellose 400 
Magnesium 
stearate 
100 Magnesium Stearate 100 
Colloidal silicon 90 Colloidal silicon 90 
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8. RESULT AND DISCUSSION 
 
U V absorption spectra of Amoxicillin trihydrate 
Amoxicillin trihydrate was dissolved in a suitable solvent and it was scanned 
at a wavelength 200nm-400nm were 0.1N HCL as a blank, using double beam 
UV/Visible spectrophotometer. The maximum wavelength is found to be 272nm. 
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FTIR of pure Amoxicillin trihydrate 
 
 
Figure 2 
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Drug Excipients compatibility study: Interaction of the drug with excipients 
was determined using FT-IR spectral analysis; these studies were mainly carried out 
to study the chemical interaction of the drug and excipients used in the formulation. 
Combination of the drug and excipients can cause changes in the chemical 
consistution of the drug. The samples were taken for FT-IR study. 
FTIR of Crospovidone 
 
                                                                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
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FTIR of Croscarmellose 
 
                                                                                                   
 
 
Figure 4 
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FTIR of Amoxicillin + Crospovidone 
 
Figure 5 
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FTIR of Amoxicillin + Croscarmellose 
                                                 
Figure 6 
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INTERPRETATION OF IR SPECTRUM 
FTIR Spectra of pure Amoxicillin trihydrate 
Table No. 10 
Frequency (cm-1) Groups Assigned Frequency (cm-1) Groups Assigned 
3040.97 C-H Aromatic 
stretching 657.20 C-S stretching 
3463.55 O-H Alcoholic 
stretching 2970.06 OH carboxylic acid 
1121.10 C-N stretching 1776.91 C=O stretching 
3170.99 N-H Amide 
stretching 1250.63 C-O stretching 
1687.66 C=O Amide 
stretching 1250.63 C-O stretching 
FTIR Spectra of Crospovidone 
Table No. 11 
Frequency (cm-1) Groups Assigned 
3448.06 N-H stretching 
2928.80 C-H stretching 
1655.16 C=O stretching 
1292.52 C-N stretching 
 
FTIR Spectra of Croscarmellose 
                                                                   Table No. 12 
Frequency (cm-1) Groups Assigned Frequency (cm-1) Groups 
Assigned 
3404.14 O-H stretching 1422.40 O-H stretching 
2925.95 C-H stretching 1326.01 C-O stretching 
1601.88 C=O stretching   
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Discussion 
 When the FTIR spectrum of the amoxicillin trihydrate (pure drug) and the 
excipients were compared, there were no major interactions showed in the spectrum. 
So the above results concluded that the amoxicillin trihydrate has no interaction with 
added excipients. 
Preformulation study of pure Drug (Amoxicillin trihydrate) 
Table No.13 
Sl. 
No. 
Parameters Result 
1 Bulk Density 0.62gm/ml 
2 Tapped Density 0.72gm/ml 
3 Angle of Repose 29.16 
4 Carr’s Index 13.88 
5 Hausner Ratio 1.16 
              
Preformulation study of the blend 
                                    Table No.14 
Batch 
Code 
Bulk 
Density 
± SD 
Tapped 
Density 
± SD 
Angle of 
repose ±SD 
 
% 
Compressibility 
±SD 
Hausner 
Ratio 
± SD 
F1 0.53±0.124 0.67±0.024 30.00±2.55 17.91±0.834 1.21±0.016 
F2 0.51±0.0124 0.61±0.0192 29.28±2.60 14.71±1.36 1.17±0.021 
F3 0.53±0.0126 0.64±0.0081 35.02±2.55 17.18±1.51 1.20±0.014 
F4 0.54±0.0124 0.64±0.0192 34.12±2.26 15.62±0.83 1.18±0.016 
F5 0.55±0.0126 0.63±0.024 28.17±2.60 12.69±1.36 1.14±0.021 
F6 0.52±0.0124 0.62±0.0192 29.15±2.55 16.12±1.51 1.19±0.016 
F7 0.55±0.0126 0.66±0.024 32.15±2.26 16.66±0.83 1.20±0.014 
F8 0.51±0.0124 0.61±0.0192 36.21±2.60 16.39±1.36 1.19±0.021 
F9 0.53±0.0124 0.62±0.0081 34.12±2.55 14.51±1.36 1.16±0.014 
F10 0.54±0.124 0.64±0.024 30.12±2.26 15.62±1.51 1.18±0.014 
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Discussion 
• Amoxicillin trihydrate in powder form were investigated for various 
physical parameters. The result revealed that it has better flow property, 
bulk density, tapped density and the compressibility and Hausner ratio 
confirmed its better flow property. 
• Amoxicillin trihydrate and excipients in the blend state had evaluated for its 
preformulation property. Because it has great role in preparation of the 
tablets. They showed better flow property and compressibility and Hausner 
ratio had showed its better suitability for the direct compression and wet 
granulation method.  
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Evaluation of Amoxicillin trihydrate dispersible tablets 
Table No.15 
 
 
 
 
 
 
Test 
Hardness 
(N) 
±SD 
Friability 
(%) 
±SD 
Thickness 
(mm) 
±SD 
Average 
weight 
(mg) 
±SD 
Disintegration 
time 
(sec) 
±SD 
Drug 
content 
(%) 
±SD 
F1 130±7.84 0.25±0.07 3.61±0.09 319±1.22 132±7.36 98.32±1.15 
F2 118±4.69 0.31±0.03 3.68±0.06 322±1.32 150±9.89 97.65±1.44 
F3 111±12.97 0.42±0.06 3.46±0.04 319.5±1.24 140±8.63 98.09±1.48 
F4 110±7.84 0.21±0.07 3.50±0.06 322±1.22 96±9.89 96.02±1.15 
F5 138±4.69 0.35±0.03 3.52±0.09 320±1.24 120±7.36 97.50±1.48 
F6 111±7.84 0.21±0.07 3.41±0.06 319±1.32 150±8.63 99.54±1.44 
F7 128±4.69 0.35±0.06 3.68±0.09 323±1.22 96±7.36 95.64±1.15 
F8 130±12.97 0.25±0.03 3.52±0.04 320±1.24 72±9.89 99.32±1.48 
F9 128±7.84 0.32±0.07 3.60±0.09 321±1.32 64±7.36 98.54±1.15 
F10 118±4.69 0.31±0.03 3.55±0.06 320±1.24 25±8.63 101.15±1.44 
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• Comparison of disintegration time of various formulation 
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• Comparison of Assay of various formulations 
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• Comparison of Disintegration Time of various formulation (seconds) 
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Figure 9 
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Dissolution profile of Innovator formulation 
Table No.16 
 
  
 
                                        
 
 
 
 
 
 
 
 
 
 
Dissolution Profile of F1 
                                                                       Table No.17 
Sl. 
No 
Time 
(min) 
Amount of 
drug release 
%drug 
release 
Cumulative% 
release 
1 5 30.8 12.32 12.32 
2 10 58.2 23.28 23.29 
3 15 130.7 52.28 52.30 
4 20 185.9 74.36 74.41 
5 25 209.6 83.34 83.42 
6 30 226.4 90.56 90.65 
7 35 235.3 94.12 94.22 
8 40 250.8 100.32 100.42 
Sl. 
No 
Time 
(min) 
Amount of 
drug release 
%drug 
release 
Cumulative % 
release 
1 5 24.3 9.72 9.72 
2 10 51.4 20.54 20.55 
3 15 110.6 44.24 44.26 
4 20 151.2 60.48 60.52 
5 25 170.5 68.20 68.26 
6     30 198.9 79.56 79.63 
7 35 209.8 83.92 84.00 
8 40 221.4 88.5 88.59 
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Dissolution profile of F2 
                                                     
Table No.18 
 
 
 
 
 
 
                                         
 
 
                                    
 
 
Dissolution profile of F3 
Table No.19 
. 
 
 
 
 
 
 
Sl. 
No 
Time 
(min) 
Amount of 
drug release 
%drug 
release 
Cumulative% 
release 
1 5 20.8 8.32 8.32 
2 10 48.6 19.44 19.45 
3 15 110.3 44.12 44.14 
4 20 160.8         64.32 64.36 
5 25 185.4 74.16 74.23 
6 30 198.3 79.32 79.40 
7 35 204.4 81.76 81.84 
8 40 216.0 86.4 86.49 
Sl. 
No 
Time 
(min) 
Amount of 
drug release 
%drug 
release  
Cumulative% 
release 
1 5 25.4 10.16 10.16 
2 10 51.3 20.52 20.53 
3 15 120.6 48.24 48.26 
4 20 167.4 66.96 67.01 
5 25 190.8 76.36 76.43 
6 30 210.8 84.32 84.40 
7 35 218.4 87.36 87.45 
8 40 225.9 90.36 90.45 
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Dissolution profile of F4 
Table No.20 
 
Dissolution profile of F5 
Table No.21 
 
 
 
 
 
 
 
 
 
 
 
 
Sl. 
No 
Time 
(min) 
Amount of 
drug release 
%drug 
release 
Cumulative % 
release 
1 5 18.9 7.56 7.56 
2 10 49.5 19.8 19.80 
3 15 110.6 44.24 44.26 
4 20 143.1 57.24 57.28 
5 25 165.6 66.24 66.30 
6 30 190.8 76.32 76.39 
7 35 208.4 83.36 83.44 
8 40 219.6 87.84 87.93 
Sl. 
No 
Time 
(min) 
Amount of 
drug release 
%drug 
release 
Cumulative % 
release 
1 5 25.4 10.16 10.16 
2 10 52.2 20.88 20.89 
3 15 101.4 40.56 40.58 
4 20 140.8 56.32 56.36 
5 25 160.3 64.12 64.18 
6 30 186.4 74.56 74.63 
7 35 201.6 80.64 80.72 
8 40 215.1 86.04 86.12 
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Dissolution profile of F6 
Table No.22 
 
 
Dissolution profile F7 
Table No.23 
 
 
 
 
 
 
 
 
 
 
                            
                                                                                            
Sl. 
No 
Time (min) Amount of 
drug release 
%drug 
release 
Cumulative % 
release 
1 5 15.1 6.04 6.04 
2 10 30.6 12.24 12.24 
       3 15 65.4 26.16 26.17 
4 20 110.7 44.28 44.30 
5 25 120.4 48.16 48.20 
6 30 127.8 51.12 51.17 
7 35 138.6 55.44 55.49 
8 40 149.4 59.7 59.76 
Sl. 
No 
Time 
(min) 
Amount of 
drug release 
%drug 
release 
Cumulative % 
release 
1 5 22.3 8.92 8.92 
2 10 54.9 21.96 21.96 
3 15 98.4 39.36 39.38 
4 20 119.7 47.88 47.92 
5 25 130.6 52.24 52.29 
6 30 175.5 70.2 70.20 
7 35 201.3 80.52 80.59 
8 40 221.4 88.56 88.64 
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Dissolution Profile of F8 
Table No.24 
 
Dissolution profile of F9 
TableNo.25 
                                    
 
 
 
                                      
 
 
 
 
 
 
 
 
Sl. 
No 
Time (min) Amount of 
drug release 
%drug 
release 
Cumulative% 
release 
1 5 22.6 9.04 9.04 
2 10 54 21.6 21.61 
3 15 95.3 38.12 38.14 
4 20 121.5 48.6 48.64 
5 25 146.9 58.76 58.81 
6 30 166.5 66.6 66.6 
7 35 202.4 80.96 81.03 
8 40 225.6 90.16 90.24 
Sl. 
No 
Time (min) Amount of 
drug release 
%drug 
release 
Cumulative% 
release 
1 5 19.7 7.88 7.88 
2 10 49.5 19.8 19.8 
3 15 99.3 39.72 39.74 
4 20 130.3 52.12 52.16 
5 25 160.2 64.08 64.13 
6 30 180.1 72.04 72.11 
7 35 205.4 82.16 82.24 
8 40 225.9 90.36 90.45 
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Dissolution profile of F10 
Table No.26 
 
 
 
 
 
 
 
 
 
 
 
 
Sl. 
No. 
Time 
(min) 
Amount of 
drug release 
%drug 
release 
Cumulative% 
release 
1 5 28.3 11.32 11.32 
2 10 57.6 23.04 23.05 
3 15 135.7 54.28 54.30 
4 20 198.9 79.56 79.62 
5 25 205.2 82.2 82.28 
6 30 220.4 88.16 88.25 
7 35 230.7 92.28 92.37 
8 40 248.8 99.01 99.11 
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Comparison of % drug release of various formulation.  
Cumulative % drug released vs time in min 
0
20
40
60
80
100
120
0 5 10 15 20 25 30 35 40 45
%
cu
m
u
la
ti
v
e
 r
e
le
a
se
 
Time (min) 
Control
F1
F2
F3
F4
 
                                                                                            Figure 10 
0
20
40
60
80
100
120
0 5 10 15 20 25 30 35 40 45 50
%
cu
m
u
la
ti
v
e
 r
e
le
a
se
 
Time (min) 
Control
F5
F6
F7
F8
F9
                                                                  Figure 11 
 
                                                                                                               Results and discussion 
 
Dept. of Pharmaceutics, KMCP            Page 86 
 
 
 
0
20
40
60
80
100
120
0 5 10 15 20 25 30 35 40 45
%
 c
u
m
u
la
ti
v
e
 r
e
le
a
se
 
Time (min) 
Control
F10
 Figure12 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                               Results and discussion 
 
Dept. of Pharmaceutics, KMCP            Page 87 
 
 
HPLC Chromatogram of formulations (Assay): 
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Discussion 
• F1: [with Crospovidone]; The tablet showed very high disintegration 
time, but shows good hardness and friability and also with minimum deviation 
in weight and thickness. The releases of the drug from the tablets were below 
the limits. It also passed the fineness of dispersion. 
• F2: [with sodium starch glycolate]; The disintegration time of the 
tablet is higher than the above formulation. Also showing a good hardness and 
friability and minimum deviation in the thickness, also the weight variations 
were within the limits. The release of the drug was poor when compared to the 
above formulation and it was not within the limits.  
• F3 [with Croscarmellose]; In this formulation the addition of the 
croscarmellose had decreased the disintegration time when comparing to the 
sodium starch glycolate. Also passed the fineness of dispersion. Shows a 
better release of the drug from the tablet. 
• F4 [with dispersible cellulose]; This formulation was prepared by the 
wet granulation method, which showed a decreased disintegration time. With a 
minimum deviation in the parameters. The wet granulation is a time 
consuming and will cause high production cost. This had resulted in the 
rejection of the wet granulation in this study and was continued with direct 
compression method. The release of the drug from the formulation is 
decreased comparing to the above formulation.  
 The failure of the single disintegrants to produce good characteristics 
had resulted in the use of the combination of the disintegrants in the preceding 
formulations. 
• F5 [with maize starch and crospovidone]; They showed an increase in 
the disintegration time and the release of the drug was below the limits 
specified. This limitation in the formulation were tried to be overcomed in the 
next formulation. 
• F6 [with maize starch and sodium starch glycolate]; This formulation 
shows increased disintegration time and the dissolution parameters were 
below the limits. They passed the dispersion test and other parameters were 
within the limits. 
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• F7 [with maize starch and croscarmellose]; Formulation which shows a 
decreased disintegration time with better hardness. The releases of the drug 
from the tablet were decreased considering the above formulation. They 
passed the dispersion test. 
• F8 [with maize starch, crospovidone and croscarmellose]; This 
formulation results better disintegration time and increased drug release when 
comparing to the above formulations.  They also passed the dispersion test. 
• F9 [with sodium starch glycolate and croscarmellose]; When 
compaired to the previous formulations, this formulation showed an decrease 
in the disintegration time of 64 sec with sufficient thickness and hardness. It 
also shows increased drug release with minimum deviation in the weight 
variation. It also passes the dispersion test. 
 The defects in these formulations are eradicated in the preceding 
formulation with the replacement of the sodium starch glycolate with 
crospovidone in the preblending stage. 
 
•  F10 [with crospovidone and croscarmellose]; When compared to 
the previous formulations the combination of the crospovidone and 
croscarmellose shows excellent disintegration time of 25 seconds. They also 
showed good dissolution profile within 40 minutes (99.11).  This formulation 
which shows good characteristic on the evaluation of the tablet. Also passed 
the dispersion test. 
 So this formulation showing disintegration of 25 seconds and drug 
release of 99.11% was found to be excellent dispersible tablet satisfying all 
the requirements for dispersible tablet has considered as the optimized 
formulation. 
It was later considered for the thermal studies, X ray diffraction studies and 
evaluated for the stability of the tablet under different conditions. 
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Discussion 
 
 Differential Thermal Analysis (DTA) 
 The DTA thermogram studies were carried out to determine the thermal 
compactability of the excipients with the drug in the optimized formulation.  
 
 The Tg values of the Amoxicillin trihydrate (pure drug) was 196.22°C 
 
 When DTA thermogram for Amoxicillin trihydrate and optimized formulation of 
amoxicillin trihydrate dispersible tablet were compared, the Tg value of the pure drug 
was situated within the Tg values of dispersible tablet revealed that there was no 
interaction between pure drug and excipients used in the formulation. 
   
  X Ray diffration studies 
 The X Ray diffraction studies were carried out to determine the interaction of the 
amoxicillin trihydrate with the excipients. The X Ray diffraction which shows no 
interaction of the drug with the excipients. 
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Stability study 
Best formulation in this work was selected for the stability studies. In this study 
the tablet had undergone through different environmental conditions to evaluate its 
stability in the different environment. It will explain the stability of the tablet, 
following condition are maintained in the stability studies: 
• 30ºC / 65% RH analyzed at a time interval of 1 month up to 3 months 
• 40ºC / 75% RH analyzed at a time interval of 1 month up to 3 months 
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Stability studies of formulation F10 at temperature 30ºC / 65% RH 
Table No.27 
 
                                         Dissolution profile of F10  
                                                Table No.28 
 
 
 
 
Properties Control After 1month After 2 month After 3 month 
Assay (%) 99.15 98.95 98.53 98.20 
Disintegration 
time (min) 
0.25 0.28 0.30 0.32 
Hardness (N) 118 118 115 114 
Friability (%) 0.31 0.31 0.29 0.25 
Time 
(min) 
Cumulative % Drug Release 
Control After1 month 
 
After2 month After3 month 
5 11.32 11.25 11.05 10.94 
10  23.05 22.94 22.68 22.34 
15 54.30 54.20 53.99 53.78 
20 79.62 79.40 79.05 78.88 
25 82.28 82.01 81.90 81.62 
30 88.25 88.05 87.90 87.65 
35 92.37 91.21 90.80 89.05 
40 99.11 97.96 96.86 95.01 
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 Stability studies of formulation F10 at temperature 40ºC / 75% RH 
Table No.29 
 
Dissolution profile of F10 
Table No.30 
 
 
 
 
Properties Control After 1month After 2 month After 3 month 
       Assay (%) 99.15 98.84 98.36 98.14 
Disintegration 
time (min) 
0.25 0.30 0.34 0.39 
Hardness (N) 118 115 110 104 
Friability (%) 0.31 0.29 0.28 0.24 
Time 
(min) 
 Cumulative % Drug Release 
Control After 1 month After 2 month After 3 month 
5 11.32 11.10 10.95 10.50 
10  23.05 22.50 21.85 20.66 
15 54.30 53.90 53.40 53.05 
20 79.62 78.11 77.72 77.48 
25 82.28 81.80 81.58 80.90 
30 88.25 87.95 87.65 87.06 
35 92.37 91.10 90.80 89.05 
40 99.11 97.34 96.26 92.45 
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HPLC chromatogram of F10 : 
 Stability studies of formulation F10 at temperature 30ºC / 65% RH  
   ( After 1 month) 
 
 Stability studies of formulation F10 at temperature 30ºC / 65% RH  
    (After 2 month) 
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 Stability studies of formulation F10 at temperature 30ºC / 65% RH  
    ( After 3 month) 
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 Stability studies of formulation F10 at temperature 40ºC / 75% RH  
    ( 1 month)  
 
   Stability studies of formulation F10 at temperature 40ºC / 75% RH  
     (2 month) 
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 Stability studies of formulation F10 at temperature 40ºC / 75% RH 
    (3 month) 
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Dissolution profile of F10 at 30°C and 65% RH 
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Discussion 
 The tablets were wrapped in an aluminum foil, packed in black PVC bottles and 
placed in stability chamber at 30ºc, 65% RH and 40ºc, 75% RH for three month. At 
the end of each month these tablets were analysed for various tests. When the final 
and initial results were compared for the stability batch, it was concluded that there 
was a considerable deviation in the tablet properties. It also shows good disintegration 
and drug release studies shows no drastic change in the release of drug form the 
formulation. This concluded that the optimized formulation shows better stability in 
the above conditions. 
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Kinetics of drug release 
Zero order release 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zero order kinetics 
R2 0.9912 
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FIRST ORDER RELEASE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First order kinetics 
R2 0.989 
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Higuchi Plot 
 
                                                                                         
 
 
 
 
 
 
 
 
 
 
 
 
 
Higuchi release kinetics 
R2 0.953 
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Korsemeyer – Peppas model  Kinetics Plot 
 
  
 
 
 
 
Discussion 
The optimized formulation F10 up on kinetic treatment releases the drug by 
zero order release kinetics. 
A Plot of cumulative % drug release versus time showed linearity. From the 
plot correlation factor value was found to be 0.9912 
 
Korsemeyer – Peppas 
n  0.7118 
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9. CONCLUSION 
 
The aim of the present work was to study the effects of different disintegrants 
on Amoxicillin trihydrate dispersible tablet and to develop a formulation in a low 
production value, using cheaper raw material but this raw material shows problems in 
the release of the drug from the formulation. The Amoxicillin trihydrate is formulated 
with different disintegrants at various amounts in single and in combination. Ten 
formulations were developed with four disintegrants using direct compression method 
and wet granulation method. Each formulation composed of drug and disintegrants at 
various amount. The disintegrants used in this study are maize starch, crospovidone, 
croscarmellose, sodium starch glycolate etc. 
 
The Preformulation studies and the evaluation studies of the tablet were done 
and found to be within the limits of the IP. The In-vitro drug release studies are 
conducted and compared with a standard formulation. 
 
The formulation F10 formulated with the combination of Crospovidone and 
Croscarmellose as disintegrating agents was found to be the optimized formulation. 
The formulation F10 also exhibited better disintegration time (25 sec) which 
according to the IP limits is within 3 min. Formulation also shows passes the 
dispersibility test. 
 
             The results of dissolution studies indicated that the formulations F3, F8, F9 
and F10, were successful and exhibited drug release pattern very close to innovator 
drug release profile but the drug release of F10 was found to be better than other 
formulation i.e. (99.11), also the key factor of a dispersible tablet i.e. disintegration 
time was found to be much better than any other formulation i.e. (25 seconds). Hence 
F10 was selected as the optimized formulation.  
 
The Differential Thermal Analysis (DTA) shows that the developed 
amoxicillin trihydrate dispersible tablet formulation shows better thermal stability. 
The X Ray diffraction studies also show no interaction of the drug and excipients. 
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The formulation F10 also passed the test for stability, (30ºc / 65% RH and 40ºc / 75% 
RH) for three months. The phenomenon of optimized drug release follows Zero order 
and Korsemeyer-Peppas model. 
 
The above study demonstrated that optimized concentrations of disintegrants 
and excipients ratios could be successfully employed for formulating amoxicillin 
trihydrate dispersible tablet. Hence it can be concluded that the above formulation of 
the amoxicillin trihydrate dispersible tablet shows a better drug release, disintegration 
time and stability. The production value of this formulation is also lower when 
compared to other formulations. So the formulation F10 is a successful formulation 
which has low production and high therapeutic efficacy.  
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